# Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients-A Comprehensive Review

Benoît Henry, Alain Lefevre Utile, Stephane Jaureguiberry, Adela Angoulvant

► To cite this version:

Benoît Henry, Alain Lefevre Utile, Stephane Jaureguiberry, Adela Angoulvant. Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients-A Comprehensive Review. Journal of Fungi, 2025, 11 (4), pp.298-298. 10.3390/jof11040298. hal-05040074

HAL Id: hal-05040074

https://hal.science/hal-05040074v1

Submitted on 22 May 2025

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
Review

# Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients—A Comprehensive Review

Benoît Henry <fnref n="1" />, Alain Lefevre Utile <fnref n="2" /> ID, Stephane Jaureguiberry <fnref n="1" />,<fnref n="3" /> ID and Adela Angoulvant <fnref n="4" />,*

**Abstract:** Intra-abdominal and gastrointestinal mucormycosis are less frequent than rhino-orbito-cerebral and pulmonary mucormycosis, but highly lethal. Their diagnosis remains challenging due to the non-specific clinical presentation. We collected English-language cases of intra-abdominal and gastrointestinal mucormycosis in non-haematological and non-neonatal patients published up to October 2024. This review analysed the epidemiological, clinical, and therapeutic charts of 290 cases. A proportion of 53.4% were reported from India and the USA. The main predisposing conditions were diabetes, solid organ transplant, ICU, and corticosteroid treatment. The most common site was the stomach (53.8%). Gastrointestinal perforation, skin breakdown, and abdominal wall infection were sources of intra-abdominal localisation. The most common symptoms were abdominal pain, vomiting, and gastrointestinal bleeding. The diagnosis relied on histology (93.8%), mycology with microscopy and culture (38.8%), and molecular methods (9.9%). Mortality (52.9%) was lower when treatment was intravenous amphotericin B, combined or not with surgery. Prompt treatment, essential for a favourable outcome, relies on early suspicion and diagnosis. Gastrointestinal and intra-abdominal mucormycosis should also be suspected in patients admitted in ICU with ventilation/nasogastric tube and corticosteroids and those with abdominal trauma or surgery, presenting abdominal distension, pain, and GI bleeding. Mycological diagnosis including direct examination, culture and Mucorales qPCR on tissue should assist with rapid diagnosis and thus treatment.

**Keywords:** mucormycosis; gastrointestinal; intra-abdominal; non-haematological; non-neonate; review

## 1. Introduction

Mucormycoses are life-threatening invasive infections caused by fungi of the order *Mucorales*, which until the last decade were known as Zygomycetes. Based on molecular phylogenetic analysis, taxonomy has evolved, the phylum *Zygomycota* has been abandoned, and these opportunistic human pathogens have been placed in the order Mucorales within the families Cunninghamellaceae, Lichtheimiaceae, Mucoraceae, Saksenaceae, and Syncephalastraceae [1,2]. Of more than 30 pathogenic species, those belonging to the genera *Rhizopus*, *Mucor*, and *Lichtheimia* (formerly *Absidia*) are reported to be responsible for most human mucormycoses [2,3]. Their identification has often been based on phenotypic characteristics, which are currently considered to be less accurate than molecular identification.

<figure><img src="image_2.png" /></figure>

check for
updates

Academic Editor: Vincent Bruno

Received: 2 March 2025

Revised: 30 March 2025

Accepted: 4 April 2025

Published: 9 April 2025

**Citation:** Henry, B.; Lefevre Utile, A.; Jaureguiberry, S.; Angoulvant, A. Gastrointestinal and Intra-Abdominal Mucormycosis in Non-Haematological Patients—A Comprehensive Review. *J. Fungi* 2025, 11, 298. https://doi.org/10.3390/jof11040298

**Copyright:** © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

<footnote n="1">¹ Service des Maladies Infectieuses et Tropicales, APHP, Hôpital Universitaire de Bicêtre, 94275 Le Kremlin-Bicêtre, France</footnote>

<footnote n="2">² Service of Paediatrics, Department Women-Mother-Child, Lausanne University Hospital, 1005 Lausanne, Switzerland</footnote>

<footnote n="3">³ Centre de Recherche en Epidémiologie et Santé des Populations (CESP), U1018, INSERM, 94807 Villejuif, France</footnote>

<footnote n="4">⁴ Faculty of Medicine, University of Paris Saclay, AP-HP, 94275 Le Kremlin-Bicêtre, France</footnote>

<footnote>* Correspondence: adela.angoulvant@gmail.com</footnote>
The worldwide increase in the number of cases during the last decades and the outbreak of mucormycosis in the context of the COVID-19 pandemic led the WHO to designate Mucorales as priority pathogens [4–10]. Infection usually occurs in debilitated patients such as those with haematological malignancies and bone marrow transplantation, solid organ transplantation (SOT), iron overload, diabetes mellitus, and the use of corticosteroids [3]. However, there have been reports of mucormycosis in immunocompetent hosts with trauma or burns over the last three decades [11–16].

Pulmonary, rhinocerebral, sinonasal, sino-orbital, and cutaneous localisations are the most common, accounting for more than 70% of cases. Gastrointestinal (GI) localisation is the least common, estimated at 5–13% of mucormycosis cases, and other intra-abdominal (IA) localisations are even rarer [3,17–19]. Their diagnosis remains a challenge due to the non-specific clinical presentation, especially when they occur outside the usual contexts such as those with haematological malignancies, neutropenia, SOT, and neonates [20,21].

We report here a comprehensive review of human mucormycoses with GI and IA localisations in patients without haematological malignancies and outside the neonatal context.

## 2. Patients and Methods

### 2.1. Search

We reviewed IA and GI mucormycoses cases from PubMed according to the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines for systematic reviews [22].

Each of the following key words were used: human, mucormycosis, zygomycosis, phycomycosis, abdominal, gastric, intestinal, colic, peritoneal, splenic, hepatic, disseminated, *Rhizopus*, *Mucor*, *Lichtheimia*, *Absidia*, *Rhizomucor*, *Apophysomyces*, *Saksenaea*, *Syncephalasstrum*, *Cunninghamella*, and *Mucorales*. Renal and urinary tract infections (UTIs) without abdominal or peritoneal cavities involvement were not included in this review. Lists of articles in CSV (comma-separated values) format were generated and saved from PubMed, and then converted to Excel format.

The search was completed by reviewing the reference sections of original articles, of reviews, case series including those with pooled analysis and case reports and adding those that were not present in the PubMed CSV and summary files. The same inclusion criteria were used as for the PubMed search.

The inclusion criteria for this review were as follows: (1) articles in the English language; (2) absence of neonatal context and/or haematological disease and/or documented neutropenia; (3) documentation of proven *Mucorales* infection either histologically or by culture, or by molecular methods according to the European Organisation for Research and Treatment of Cancer (EORTC) and the Mycoses Study Group Education and Research Consortium (MSGERC) criteria for invasive fungal disease [23]; (4) cases with documentation of age and sex of the patient, underlying diseases/predisposing factors, site(s) of infection, methods of diagnosis, treatment, and outcome. Poorly described cases, including those from reviews and pooled cases, were excluded.

Data of sex, age, underlying conditions, infection site, fungal agent, concomitant other infections, diagnostic methods (cytopathology, microscopic direct examination, cultures, and molecular methods), and antifungal and surgical treatment and outcome at 3 months after diagnosis were collected in an Excel table.

### 2.2. Definitions

GI and IA mucormycoses were defined as proven infections according to the EORTC and MSGERC criteria for invasive fungal diseases [23], the sites of infection being oesopha-
gus, stomach, and small and large bowel and, respectively, abdominal wall, peritoneum, omentum, mesenteron, liver, spleen, and adrenal gland.

### 2.3. Statistics

A descriptive analysis of data and maps was performed using Microsoft Excel®. Categorical variables were expressed as the number of cases and as a percentage of the total (%). Comparisons between groups were made using Fisher's exact test for continuous variables. *p* values < 0.05 were considered statistically significant.

## 3. Results

Our literature search of PubMed yielded a total of 363 articles. After excluding duplicate, non-English, and irrelevant articles, a total of 142 studies reported individual patient data. Together with the studies retrieved from the additional search of reference sections, 116 cases from 108 articles for a total of 290 cases were included (Supplementary Tables S1 and S2). A flowchart of the sorting process is shown in Figure 1.

The first documented case was published in 1960. The chronological increase in the number of cases since the 2000s is illustrated in Figure 2.

Among the included studies, the countries reporting the highest number of GI/IA mucormycosis were India (93/290, 32.06%), USA (62/290, 21.37%), South Africa (19/290, 6.55%), Spain (14/290, 4.83%), and China (13/290, 4.48%) (Figure 3, Supplementary Table S1).

### 3.1. Demographic Data and Underling Conditions

Age information was available for 288 cases. The median age of included GI/IA mucormycosis patients was 45 years [1.5 month–86 years] and the majority of them were men (192/288, 66.67%). Thirty cases were reported in patients under 18 years, and 20 patients have age under 16 years.

Data of underling disease or condition were available for 281 cases. Their frequency varied across the decades and the countries (Table 1 and Supplementary Figures S1 and S2). A majority of cases (220/281, 78.01%) had two or more underling diseases/conditions. Diabetes was the most common comorbidity (70/282, 24.82%), with no significant difference between men (39/70, 55.71%) and women (31/70, 44.29%). Of the patients with diabetes, 14.8% presented with ketoacidosis (KA).

SOT (46/282, 16.31%) with kidney and liver transplant was the most frequent (20/282, 7.09% and 15/282, 5.31%, respectively), and renal failure (36/282, 12.76%) were the most frequent comorbidities after diabetes. Abdominal surgery was reported in 42/282 cases (14.89%), with 37.5% (18/48) being performed for with GI perforation or peritonitis.

Cases associated with COVID-19 accounted for 8.51% of all cases and for 18.46% (24/130) of cases since 2020. Of the 24 cases, 14 (58.33%) occurred in India.

Intensive care unit (ICU) stay (67/282, 23.75%) and corticosteroid treatment (45/282, 15.96%) other than that prescribed in the context of SOT were common conditions in GI/IA mucormycosis cases.

Underlying conditions varied according to the GI and IA localisation (Figure 4). GI localisations had varied underling conditions. On the contrary, IA abscesses and abdominal wall infection, abdominal injury and surgery were the main, whereas ICU stay was not reported.
<figure><img src="image_3.png" /><figcaption>**Figure 1.** PRISMA 2020 flow diagram [22]. a. Of these, 9 articles reported cases which met the other inclusion criteria of gastrointestinal and intra-abdominal mucormycosis: Spanish language (n = 2: 1 gastric, 1 intestinal), French (n = 2: 1 hepatic, 1 disseminated with hepatic, splenic, and gastric involvement), German (1 gastro-duodenal), Italian (1 peritoneal), Czech (1 gastric), Norwegian (1 gastric),</figcaption></figure>
Chinese (1 gastric). b. Irrelevant title or abstract: not mucormycosis (e.g., blastomycosis); neonatal or haematological, including neutropenia, contexts; no intra-abdominal or digestive proven localisation. c. Other sources: ScienceDirect.com, Elsevier, journal site (e.g., The American Journal of Gastroenterology—ACG).

<figure><img src="image_4.png" /><figcaption>**Figure 2.** Number of published cases per year from 1960 to October 2024.</figcaption></figure>

<figure><img src="image_5.png" /><figcaption>**Figure 3.** Geographical distribution of cases. NA, not available; LFU, lost to follow-up.</figcaption></figure>
<table><caption>**Table 1.** Underlying disease or condition. The sum of underlying diseases/conditions is greater than 291 (100%) because in most cases there was more than one. Percentage calculated only for number ≥ 5. CAPD, Continuous ambulatory peritoneal dialysis; HIV, human immunodeficiency virus; AIDS, acquired immune deficiency syndrome; ARDS, acute respiratory distress syndrome; ECMO, extra corporeal membrane oxygenation; ICU, intensive care unit. a. Metabolic acidosis does not include diabetic keto-acidosis. b. Other: (i) GI/IA, pelvic condition (n = 25): gastritis (n = 3), gastric erosion, adenocarcinoma, portal gastropathy, gastroparesis, peptic ulcer history, gastro-enteritis, *Salmonella* enteritis, *C. difficile* colitis, pan-colitis, digestive adenocarcinoma, diarrhoea, pancreatitis, peritoneal infection/peritonitis history (n = 6), breach in CAPD sterile technique, percutaneous drainage of renal collection, postpartum haemorrhage, testicular cancer + chemotherapy, sider bite (n = 1); (ii) thoracic/pulmonary condition (n = 18): ARDS (9), COPD (n = 3), respiratory failure, emphysema, H1N1 pneumonia, pulmonary tuberculosis, pleural infection, chest stab, thoracic surgery (n = 1); (iii) infection history (n = 4): typhoid fever (2), rhino-facial mucormycosis, *P. falciparum* malaria (n = 1); iron overload/transfusions (n = 5); (ivii) miscellaneous (n = 12): tobacco use (n = 5), burn (n = 2), back trauma, pesticide ingestion, cytopenia, haemolytic uremic syndrome, motor hemiplegia (n = 1).</caption><thead><tr><th rowspan="2">Underlying Disease/Condition</th><th colspan="2">Cases</th></tr><tr><th>Number</th><th>Percentage</th></tr></thead><tbody><tr><td>Diabetes mellitus, of which<br>with ketoacidosis (n = 10)</td><td>70<br>10</td><td>24.8<br>3.5</td></tr><tr><td>Solid organ transplantation</td><td>46</td><td>16.3</td></tr><tr><td>Kidney only</td><td>20</td><td>7.1</td></tr><tr><td>Liver only</td><td>14</td><td>5</td></tr><tr><td>Other: kidney + liver (n = 4); heart (n = 3); heart + lung (n = 2), kidney + pancreas, lung,<br>multi-organs (n = 1)</td><td>12</td><td>4.2</td></tr><tr><td>Autoimmune disease</td><td>11</td><td>3.9</td></tr><tr><td>Inflammatory bowel disease (n = 4)</td><td></td><td></td></tr><tr><td>Systemic lupus erythematosus (n = 3),</td><td></td><td></td></tr><tr><td>Inflammatory vasculitis (n = 2),</td><td></td><td></td></tr><tr><td>Sarcoidosis and rheumatic heart disease (n = 1)</td><td></td><td></td></tr><tr><td>Renal failure/dysfunction, of which 10 occurred in diabetic patients</td><td>36</td><td>12.8</td></tr><tr><td>CAPD</td><td>21</td><td>7.5</td></tr><tr><td>Haemodialysis,</td><td>11</td><td>3.9</td></tr><tr><td>No replacement for kidney dysfunction (n = 4)</td><td></td><td></td></tr><tr><td>Hepatic failure/dysfunction, of which</td><td>19</td><td>6.7</td></tr><tr><td>Cirrhosis</td><td>8</td><td>2.8</td></tr><tr><td>Impaired immune response:</td><td>18</td><td>6.4</td></tr><tr><td>HIV infection, of which</td><td>10</td><td>3.5</td></tr><tr><td>AIDS,</td><td>6</td><td>2.1</td></tr><tr><td>CD4 count > 200/mm³ (n = 4)</td><td></td><td></td></tr><tr><td>CD4 low count or dysfunction (n = 3)</td><td></td><td></td></tr><tr><td>Splenic absence or splenectomy (n = 2)</td><td></td><td></td></tr><tr><td>Other impaired immune response: Papillon-Lefevre syndrome, Down's syndrome,<br>low absolute lymphocyte count, and<br>monocyte HLA-DR dysfunction (n = 1)</td><td></td><td></td></tr><tr><td>COVID-19</td><td>24</td><td>8.5</td></tr><tr><td>Alcohol abuse, of which hepatic failure/dysfunction (n = 2) and cirrhosis (n = 1)</td><td>23</td><td>8.1</td></tr><tr><td>Drug abuse</td><td>9</td><td>3.2</td></tr><tr><td>Malnutrition (none without other underlying condition)</td><td>5</td><td>1.8</td></tr><tr><td>Abdominal injury</td><td>22</td><td>7.8</td></tr><tr><td>Traffic accident</td><td>9</td><td>3.2</td></tr><tr><td>Blunt/stab wound</td><td>6</td><td>2.1</td></tr><tr><td>Fall/professional accident (n = 4)</td><td></td><td></td></tr><tr><td>Gunshot/bombing (n = 3)</td><td></td><td></td></tr><tr><td>Abdominal surgery, of which</td><td>42</td><td>14.9</td></tr><tr><td>for gastrointestinal perforation/peritonitis</td><td>18</td><td>6.4</td></tr><tr><td>Stay in ICU, of which</td><td>67</td><td>23.7</td></tr><tr><td>Septic shock/sepsis</td><td>25</td><td>8.9</td></tr><tr><td>Metabolic acidosis <sup>a</sup></td><td>12</td><td>4.2</td></tr><tr><td>Multi-organ failure,</td><td>16</td><td>5.7</td></tr><tr><td>Mechanical Ventilation</td><td>22</td><td>7.8</td></tr><tr><td>ECMO</td><td>5</td><td>1.8</td></tr><tr><td>Corticosteroids (excluding TOS immunosuppression),<br>of which auto-immune disease treatment (n = 5)</td><td>45</td><td>16</td></tr><tr><td>Other <sup>b</sup></td><td>50</td><td>17.7</td></tr><tr><td>None</td><td>6</td><td>2.1</td></tr></tbody></table>
<figure><img src="image_6.png" /><figcaption>**Figure 4.** Underlying diseases and conditions distribution according to the gastrointestinal (GI) and intra-abdominal (IA) localisations. For each localisation, the sum of underlying diseases/conditions is greater than the number of each localisation because in most cases there was more than one. ICU, intensive care unit; DM, diabetes mellitus; SOT, solid organ transplant; CAPD, continuous ambulatory peritoneal dialysis; NS, not specified. "Other" includes the "other" category as summarised in Table 1.</figcaption></figure>

## 3.2. Clinical and Paraclinical Presentation

The clinical and paraclinical characteristics of the cases (adult and paediatric) are shown in Supplementary Table S1. Of the 290 cases, 4 had no more precise information on the site than "GI" or "digestive". In 59 cases, more than one GI and/or IA site was reported, and in 24 cases, the mucormycosis was disseminated.

Overall, stomach (156/290, 53.79%) was the most common site, followed by intestine (78/290, 26.89%), abdominal wall (26/290, 8.93%), and peritoneum/retroperitoneum (24/290, 8.24%) (Figure 5). The distribution according to patient age was different in patients younger than 16 years, with the intestine (11/20, 55%) being the most common site, followed by the stomach (5/20, 25%), liver (3/20, 15%), and peritoneum (2/20, 10%).

The large intestine (cecum, colon, rectum, anal canal) was most commonly involved (31/78, 39.74%), followed by the small intestine (duodenum, ileum, jejunum) (17/78, 21.79%) or both.

According to publication date, the distribution of sites differs after 2000, with fewer cases of disseminated mucormycosis and more cases of stomach, intestine, and GI/IA with more than one site (Figure 6).
<figure><img src="image_7.png" /><figcaption>**Figure 5.** Gastrointestinal (GI) and intra-abdominal (IA) mucormycosis sites. Abd, abdominal; NS, not specified. Within disseminated: disseminated cases of mucormycosis with a GI and/or IA localisation.</figcaption></figure>

<figure><img src="image_8.png" /><figcaption>**Figure 6.** Site distribution (%) according to the publication period. Abd, abdominal.</figcaption></figure>

### 3.3. Clinical Presentation

Symptoms were specified for 249 cases. They were non-specific with abdominal pain or discomfort (100/249, 40.16%) being the most common, followed by vomiting/nausea (51/249, 20.48%), GI bleeding (47/249, 18.87%), and fever (45/249, 18.07%) (Figure 7). All symptoms are summarised in Table 2.
<figure><img src="image_9.png" /><figcaption>**Figure 7.** Symptoms rate (percentage). GI, gastrointestinal. Abd, abdominal. Dialysis catheter or bag or dialysate abnormalities (clogged Tenckhoff catheter, cloudy dialysis bag, or dialysate fluid). Other symptoms: acute abdomen, bowel movements, mass in epigastrium, hepato-splenomegaly, splenomegaly (HSM), paralytic ileus, pneumoperitoneum, rectum mucosal sloughing, anaemia, multi-organ failure (MOF), sepsis, and symptoms linked to other site in disseminated cases (cardiac tamponade, chest pain, dyspnoea, mental confusion).</figcaption></figure>

Endoscopy was reported in 127/291 cases of mucormycosis: 93 were gastric, 4 were gastric with another intra-abdominal site other than the intestine, 6 were gastric and intestinal, 16 were intestinal, and 6 were disseminated with gastric or intestinal localisation.

Ulcer or erosion (96, 75.6%) and necrosis (44, 34.64%) were the main endoscopic features in both gastric and intestinal lesions. These were followed by the presence of exudate, mainly green or greyish (21, 16.53%), bleeding (20, 15.74%), infiltration or proliferative lesion (19, 14.96%), and mucosal inflammation or gastritis (13, 10.23%). Necrosis was reported more frequently in gastric localisation (34.64%), whereas mucosal inflammation or congestion was reported more frequently in intestinal localisation (Figure 8).

<figure><img src="image_10.png" /><figcaption>**Figure 8.** Endoscopic features distribution according to the gastric versus the intestinal localisation.</figcaption></figure>
<table><caption>**Table 2.** Symptoms distribution for the 249 cases with available information. IA, intra-abdominal: peritoneal (n = 14), peritoneal + intra-abdominal abscess (n = 4) infection, intra-abdominal abscess. Abd. Wall, abdominal wall. GI, gastrointestinal. a. Dialysis catheter or bag or dialysate abnormalities (clogged Tenckhoff catheter, cloudy dialysis bag or dialysate fluid). b. Other symptoms: acute abdomen, bowel movements, mass in epigastrium, HSM, hepatosplenomegaly (n = 2), paralytic ileus, pneumoperitoneum (n = 2), rectum mucosal sloughing, anaemia, multi-organ failure (MOF), sepsis, and symptoms linked to other site in disseminated cases (cardiac tamponade, chest pain, dyspnoea, mental confusion). c. Other sites: spleen (n = 5), liver (n = 3), oesophagus (n = 1), mesenteron (n = 1).</caption><thead><tr><th></th><th>Stomach<br>(n = 111)</th><th>Intestine<br>(n = 33)</th><th>Peritoneal<br>(n = 13)</th><th>Abd. Wall<br>(n = 15)</th><th>Other Sites <sup>c</sup><br>(n = 10)</th><th>GI/IA, >1 Site<br>(n = 56)</th><th>Disseminated<br>(n = 16)</th></tr></thead><tbody><tr><td>Abdominal pain/discomfort</td><td>59 (53.15%)</td><td>12 (36.36%)</td><td>5 (38.46%)</td><td>3 (20%)</td><td>2 (20%)</td><td>18 (32.14%)</td><td>1 (5.88%)</td></tr><tr><td>Abdominal distension</td><td>11 (9.91%)</td><td>13 (39.39%)</td><td>2 (15.38%)</td><td>0</td><td>0</td><td>8 (14.28%)</td><td>2 (11.76%)</td></tr><tr><td>GI bleeding</td><td>52 (46.85%)</td><td>12 (36.36%)</td><td>0</td><td>0</td><td>5 (50%)</td><td>13 (23.21%)</td><td>2 (11.76%)</td></tr><tr><td>Vomiting and/or nausea</td><td>27 (24.32%)</td><td>13 (39.39%)</td><td>2 (15.38%)</td><td>1 (6.67%)</td><td>0</td><td>6 (10.71%)</td><td>2 (11.76%)</td></tr><tr><td>Fever</td><td>15 (13.51%)</td><td>3 (23.08%)</td><td>2 (15.38%)</td><td>6 (40%)</td><td>2 (20%)</td><td>1 (1.78%)</td><td>5 (29.41%)</td></tr><tr><td>Peritonitis</td><td>1 (6.67%)</td><td>6 (18.18%)</td><td>1 (7.69%)</td><td>0</td><td>0</td><td>6 (10.71%)</td><td>2 (11.76%)</td></tr><tr><td>Appetite/digestion disorders</td><td>10 (9.01%)</td><td>1 (3.03%)</td><td>0</td><td>0</td><td>1 (10%)</td><td>0</td><td>0</td></tr><tr><td>Diarrhoea</td><td>1 (0.90%)</td><td>2 (6.06%)</td><td>1 (7.69%)</td><td>0</td><td>0</td><td>2 (3.57%)</td><td>0</td></tr><tr><td>Constipation</td><td>2 (1.80%)</td><td>4 (12.12%)</td><td>0</td><td>0</td><td>0</td><td>1 (1.78%)</td><td>0</td></tr><tr><td>Cutaneous/wound abnormalities</td><td>0</td><td>2 (6.06%)</td><td>1 (7.69%)</td><td>14 (93.33%)</td><td>1 (10%)</td><td>8 (14.28%)</td><td>0</td></tr><tr><td>Dialysis catheter or bag or dialysate abnormalities <sup>a</sup></td><td>0</td><td>0</td><td>4 (30.77%)</td><td>0</td><td>0</td><td>4 (7.14%)</td><td>0</td></tr><tr><td>Renal failure</td><td>0</td><td>0</td><td>0</td><td>0</td><td>1 (10%)</td><td>7 (12.5%)</td><td>2 (11.76%)</td></tr><tr><td>Flank pain</td><td>0</td><td>0</td><td>0</td><td>0</td><td>2 (20%)</td><td>4 (7.14%)</td><td>0</td></tr><tr><td>Liver failure</td><td>2 (1.80%)</td><td>0</td><td>1 (7.69%)</td><td>0</td><td>0</td><td>2 (3.57%)</td><td>2 (11.76%)</td></tr><tr><td>Other <sup>b</sup></td><td>3 (2.70%)</td><td>1 (3.03%)</td><td>0</td><td>0</td><td>2 (20%)</td><td>5 (8.92%)</td><td>12 (70.59%)</td></tr></tbody></table>
CT scan findings were reported in 114 cases and were not specific. Their characteristics are summarised in Supplementary Table S1.

### 3.4. Diagnostic

Diagnostic methods and results are summarised in Supplementary Table S2. In 272/290 patients, cytopathology was performed on biopsy, on tissue specimen obtained during surgery and on the contents of IA collection or abscess, showing large, irregular, non-septate hyphae. In 87 cases, cytopathology was performed only on biopsy, in 112 cases only on tissue sample and in one case only on abscess content. The diagnosis was made ante-mortem in one case and post-mortem in 45 (16.36%) cases, of which 38 were autopsies and 7 post-mortem biopsies.

A basic mycological diagnosis which included microscopy and/or fungal culture was reported in 104/271 (38.37%) cases: 30 with direct examination (DE) and culture, 73 with culture only, and one with DE only. In total, 30 cases were positive by DE and 90 by culture. Of these, 77 were GI or IA specimens, 6 were GI or IA and other sites, and 7 were other sites (2 peritoneal catheter tips, 1 peritoneal dialysis bag, 1 blood culture, 1 lung specimen, 1 sputum, and 1 skin). Of the 82 cases with a positive culture from a GI and/or IA specimen, 25 were from the stomach, 22 from the abdominal wall, and 16 from the peritoneum. In 84 cases, both cytopathology and mycology were performed. In 17 cases, the diagnosis was based on mycology because the cytopathology was negative, and in 14 cases, the diagnosis was based on cytopathology because the mycology was negative.

Molecular diagnosis, based on PCR and sequencing of rDNA regions, was performed in 27 cases: 15 on tissue samples, mostly on formalin-fixed and paraffin-embedded tissue (FFPET), and 12 on fungal culture for accurate identification.

Genus and species identification were available for 94/290 (32.41%) cases: 39 cases with genus identification and 53 cases with species identification, one case where cytopathology with immunochemistry could not differentiate between *Rhizomucor* sp. and *Rhizopus* sp. and one case where the molecular method on FFPET could not differentiate between *R. oryzae* and *R. sexualis* (Table 3).

<table><caption>**Table 3.** Genus and species identification for the 95 cases for which it was reported.</caption><thead><tr><th>Identification</th><th>No (%)</th></tr></thead><tbody><tr><td><i>Rhizopus</i></td><td>52 (54.7)</td></tr><tr><td><i>Rhizopus</i> sp.</td><td>23 (24.2)</td></tr><tr><td><i>R. microsporus</i></td><td>12 (12.6)</td></tr><tr><td><i>R. microsporus</i> var. <i>rhizopodiformis</i></td><td>6 (6.3)</td></tr><tr><td><i>R. microsporus</i> var. <i>microsporus</i></td><td>1 (1)</td></tr><tr><td><i>R. microsporus</i> var. <i>azygosporus</i></td><td>1 (1)</td></tr><tr><td><i>R. oryzae</i> (arrhizus)</td><td>7 (7.4)</td></tr><tr><td><i>R. oryzae</i> or <i>R. sexualis</i></td><td>1 (1)</td></tr><tr><td><i>R. stolonifer</i></td><td>1 (1)</td></tr><tr><td><i>Rhizomucor</i> sp./<i>Rhizopus</i> sp.</td><td>1 (1)</td></tr><tr><td><i>Mucor</i></td><td>16 (16.8)</td></tr><tr><td><i>Mucor</i> sp.</td><td>13 (13.7)</td></tr><tr><td><i>M. indicus</i></td><td>2 (2.1)</td></tr><tr><td><i>M. ramosissimus</i></td><td>1 (1)</td></tr><tr><td><i>Apophysomyces</i></td><td>11 (11.6)</td></tr><tr><td><i>A. elegans</i></td><td>10 (10.5)</td></tr><tr><td><i>A. variabilis</i></td><td>1 (1)</td></tr><tr><td><i>Lichtheimia</i> (former <i>Absidia</i>)</td><td>9 (9.5)</td></tr><tr><td><i>Lichtheimia</i> (former <i>Absidia</i>) sp.</td><td>2 (2.1)</td></tr></tbody></table>
<table><caption>**Table 3.** *Cont.*</caption><thead><tr><th>Identification</th><th>No (%)</th></tr></thead><tbody><tr><td>L. corymbifera</td><td>3 (3.6)</td></tr><tr><td>L. ramosa</td><td>3 (3.6)</td></tr><tr><td>L. hongkongensis</td><td>1 (1)</td></tr><tr><td>Cunninghamella bertholletiae</td><td>2 (2.1)</td></tr><tr><td>Saksanea vasiformis</td><td>2 (2.1)</td></tr><tr><td>Syncephalastrum racemosum</td><td>1 (1)</td></tr></tbody></table>

*Rhizopus*, *Mucor*, *Apophysomyces*, and *Lichtheimia* were the most commonly isolated genera, with differences depending on the site of infection (Figure 9). *Saksanea vasiformis* and *Apophysomyces* were more frequently isolated from abdominal wall infections.

<figure><img src="image_11.png" /></figure>

**Figure 9.** *Mucorales* genus distribution according to the gastrointestinal (GI) and intra-abdominal (IA) localisation. Abd, abdominal. GI/IA, >1, GI/IA localisation with more than 1 site: *Mucor* sp. (3 with stomach infection, 2 with peritoneal infection). Disseminated: *Rhizopus* sp., all cases were from USA and Europe.

Bacterial (*Acinetobacter* sp., *Bacteroides fragilis*, *Clostridium difficile*, *Enterobacter* spp., *Enterococcus* spp., *Esterichia coli*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Stenotrophomonas maltophilia*, *Serratia marcescens*, *Satphylococcus* spp., *Streptococcus viridians*, *Legionella pneumophila*, *Mycobacterium tuberculosis* complex), viral (SARS-CoV2, HIV, H1N1 influenzae, CMV, HVA, HVB, HVC), fungal (*Candida* spp., *Aspergillus* spp., *Pneumocystis jirovecii*) or parasitic (*Strongyloides stercoralis*, *Schistosoma* sp., *Taenia solium* cysticercosis, *Plasmodium falciparum*, *Toxoplasma gondii*) co-infections were reported in 75/290 (25.6%) of the patients. They are summarised in Supplementary Table S2.

### 3.5. Management and Outcome

The management was documented in 285 out of 290 cases (Supplementary Table S2). In 40 out of 286 cases (29 diagnosed post-mortem), no treatment was recorded. The treatment modalities included antifungal therapy (AFT) (69/246, 28.16%), surgical interventions (41/246, 16.67%), and a combination of surgery and AFT (127/246, 51.62%). In eight cases, the intervention was limited to the removal of the peritoneal catheter and in two cases, to suturing the gastric ulcer.
Of the 203/290 (70%) cases for which AFT was reported, 3 did not specify the molecule. Amphotericin B (Amp B) intravenous derivatives were utilised as a first-line therapy, with Amp B deoxycholate (86/200, 43%), followed by the lipid formulations liposomal Amp B (79/200, 39.5%) and Amp B lipid complex (6/200, 3%). High-dose (≥5 mg/kg/d) administration of an Amp B lipid formulation was utilised in 34 cases. AmpB administered either as a monotherapy or in combination with other antifungal agents. In one case (abdominal wall fasciitis), Amp B deoxycholate was employed as a topical agent. Azoles, such as pozaconazole (PSZ) and isavuconazole (ISV), were predominantly utilised as maintenance therapy. PSZ was used as a first-line therapy (4/201, 2%), in combination (2/201, 1%), in combination and maintenance (3/201, 1.47%), and maintenance (28/201, 13.93%) therapy. Similarly, ISV was used as first line (2/201, 1%), in combination (2/201, 1%), and maintenance (3/201, 1.47%) therapy. Itraconazole (ITZ) was utilised as maintenance therapy in 3/201 (1.47%) cases, while fluconazole (FCZ) and ketoconazole (KTZ) were employed as a first-line therapy in 3 and 1 cases, respectively. Micafungin and caspofungin were used in combination in 7/201 (2.48%) and 2/201 (1.47%) cases, respectively. In conjunction with the administration of AFT and/or surgical intervention, a reduction in immunosuppression was reported in 16/39 (41.02%) patients with SOT for whom treatment was specified.

Outcome information at 90 days was available for 272 cases, and the 90-day mortality rate was 52.94% (see Supplementary Table S2). This mortality rate differed significantly (*p* < 0.01) according to the treatment regimen, with the highest mortality rate (83.78%) being observed in patients treated only with surgery, in comparison to all other main regimens (see Figure 10).

<figure><img src="image_12.png" /><figcaption>**Figure 10.** Outcome (%) according to the main treatment regimens. AMB d, amphotericin B deoxycholate. AMB L, amphotericin B lipid formulations.</figcaption></figure>

No significant differences were observed among the other treatment regimens, despite the lower mortality rate observed in subjects treated with Amb lipid formulations.

The mortality rate exhibited variation across different countries (Figure 3) and according to the infection sites (Figure 11). No significant differences were observed based on age, with a median age of 45 years for both survivors (0.5 y–82 y) and non-survivors (0.13 y–86 y) and between adults (52.89%) and children (53.33%).
<figure><img src="image_13.png" /><figcaption>**Figure 11.** Outcome percentage according to the infection site. GI, gastrointestinal; IA, Intra-abdominal.</figcaption></figure>

**4. Discussion**

This comprehensive review of GI and/or IA mucormycosis in non-neonatal and non-haematological contexts collected data on the epidemiology, diagnosis, management, and outcome of 290 cases between 1960 and 2024.

It is not possible to estimate the incidence or prevalence of GI and IA mucormycosis, but in the present study, the number of reported confirmed cases increased after 2010. This may reflect either a true increase in GI and/or IA mucormycosis due to increased awareness and improved diagnostic methods, or more reports of this fungal infection. For example, the outbreak of mucormycosis associated with the COVID-19 pandemic, particularly in India, led to the WHO issuing a warning on this infection. The overall prevalence of mucormycosis in India was estimated to be almost 70 times higher than that in the global data [9]. However, in this study, the prevalence of GI and IA mucormycosis in children and adults, without haematological disease and outside the neonatal context, in India was less than twice that of the USA, which ranked second in case numbers. This may be due to a lower number of cases of GI/IA infections in this population compared to India, as GI cases were reported mainly in premature neonates prior to 1990 [21], but also to the overall similar underlying diseases and conditions.

Diabetes mellitus, SOT, especially renal, and renal failure were the most common underlying diseases of GI and IA mucormycosis, with frequencies that may vary between countries (Supplementary Figure S2). Among countries with more than 10 reported cases, the percentage of cases with diabetes and renal failure (5%) was lower in South Africa, where abdominal trauma predominated (26%), and that of SOT was higher in the USA (21%) and China (23%). Cases with HIV were most commonly reported in the USA (10%) and Spain (14%) and those with COVID-19 (15%) in India and China. The percentage of cases admitted to intensive care and treated with corticosteroids was higher in Spain (64% and 71%, respectively) and lower in South Africa (5% for both). Gastric and intestinal mucosa and abdominal wall injuries, either disease-related or iatrogenic, were potential portals of entry for *Mucorales*. As for the other clinical forms, ICU admission, abdominal
surgery and corticosteroid treatment were common underlying conditions, suggesting that they may be healthcare-associated risk factors for GI and IA mucormycosis [24].

The source of GI and IA mucormycosis remains unclear, but the ingestion or introduction of Mucorales spores with contaminated food, drink, or medical devices is strongly suspected as a route of entry through the digestive tract. On the other hand, in cases with abdominal wall involvement, the main route of entry appears to be through the skin from environmental sources.

As in other studies, the stomach was the most commonly affected GI site, followed by the colon and ileum, with an inverse distribution in children under 16 years of age [21], and then liver, spleen, and IA cavity following.

As neither clinical nor CTS or USG features are specific, the diagnosis of GI mucormycosis remains a challenge with 17% of cases diagnosed post or perimortem, particularly before 2000. Abdominal distension and pain and GI bleeding as haematemesis, haematochezia or melena were the common features for GI forms or swelling, fasciitis, necrosis for IA forms with abdominal wall as the primary site. Ulceration or erosion was the most common but non-specific endoscopic GI feature. However, necrosis, reported in more than 30% of cases and reflecting vascular invasion, should be an alerting feature.

Improving the diagnostic delay is therefore important in GI ulcerations, IA abscesses and abdominal wall fasciitis, even if the patient is immunocompetent, the differential diagnosis should include mucormycosis. Microscopic examination of wet mounts with KOH or fluorescent brighteners such as calcofluor white (Sigma Aldrich, St. Louis, MO, USA) or blankophor (Tanatax Chemicals, Ede, The Netherlands) is one of the cornerstones in the diagnosis of mucormycosis [25] and strongly recommended since it provides rapid at least presumptive diagnosis [26]. However, in this study, it was only performed in 11.76% of the cases. Direct examination needs to be confirmed by histopathology for evidence of tissue invasion of non-sterile sites and by culture and/or molecular or in situ identification techniques when such assays are available [26]. Overall, fungal cultures are positive in 50% to 71% of cases of mucormycosis [17,25]. In this study, culture was only performed in 38% of cases and was positive in 74.04% of cases and similar to that reported by Didehdar et al. (14/19, 73.68%) for 87 cases reported between 2015 and 2021 [27]. This high rate may be due to publication bias.

The identification of the fungal agent was mainly based on phenotypic characteristics. Molecular methods, mainly based on PCR and the sequencing of the ITS1 and ITS2 regions of the rDNA, have been performed in 27 cases since 2003, of which 24 allowed the identification of Mucorales. Gastroenterologists and surgeons should be encouraged to send samples for mycological examination to determine the exact aetiological agent.

Worldwide, more than 90% of mucormycoses are caused by *Rhizopus* spp., *Mucor* spp. and *Lichtheimia* (formerly *Absidia*) spp. In contrast, *Cunninghamella* spp., *Apophysomyces* spp., *Saksenaea* spp., *Rhizomucor* spp., *Cokeromyces* spp., and *Syncephalastrum* each account for fewer than 5% of cases. However, there are geographical variations, with *Mucor* spp. and *Lichtheimia* spp. as secondary causes in the Americas and Europe, and *Apophysomyces* spp. as secondary causes in India [3]. The genera *Rhizopus*, *Mucor*, *Apophysomyces*, and *Lichtheimia* were identified with varying frequencies according to the site of infection (Figure 9). The genus *Apophysomyces*, with a particular emphasis on *A. elegans*, was the third most isolated genus. This is likely attributable to the inclusion of IA mucormycosis with abdominal wall start, predominantly from India, for which this genus was identified in 9/13 cases. However, it is important to note that the identification of these genera relied predominantly on phenotypic characteristics (70/94, 74.46%), which are currently considered less accurate than molecular identification. Consequently, the interpretation of genera and species epidemiology should be approached with a degree of caution.
The guidelines for the treatment of mucormycosis recommend a combination of surgical debridement and AFT with a high dose of Amp B lipid preparations of as a first-line therapy [26]. However, in settings where resources are limited, Amp B deoxycholate may be the only option. In the present review, 51.41% of the treated patients received the combined therapy with surgery and Amp B lipid preparations (39.80%) or with Amp B deoxycholate (42.78%). High-dose (≥5 mg/kg/d) of Amp B lipid formulations was used in 39.53% of cases. Since 2010, there have been reports of the utilisation of PSZ or ISZ, primarily in the context of maintenance or combination therapy.

In the present review, crude mortality at three months was 52.94%, which is comparable with that of cases with only one GI or IA localisation (40% to 50%) and lower than that of cases with more than one localisation (57%) or with disseminated infection (82%). This is consistent with previous publications, which reported a mortality between 40 and 85%, with lower mortality reported after 2010 [17,21,27–29]. The mortality rates of adults (52.89%) and children (53.33%) were comparable. This can be attributed to the exclusion of the neonatal population, in which the mortality rate of GI mucormycosis is significantly higher, ranging from 70% to 85% [27,29]. Abdominal wall mucormycosis has been documented in various case reports and reviews, predominantly concerning cutaneous localisations, with an overall mortality rate of 35% [30]. Abdominal wall mucormycosis has been documented in various case reports and reviews, predominantly concerning cutaneous localisations, with an overall mortality rate of 35%. Thus, specific mortality of abdominal wall mucormycosis with deep subcutaneous involvement (beyond the subcutaneous plane) was not reported. This review found that the mortality rate for cases involving the abdominal wall was higher (59.09%), with 53.33% of cases occurring as the sole site of infection and 71.43% of cases involving other sites.

The mortality rate exhibited a significant variation according to the treatment regimen, with the highest mortality rate (83.78%) observed in patients treated exclusively with surgery, in comparison to all other main regimens and a lower mortality rate found in subjects treated with Amb lipid formulations with or without surgery. The low mortality (25%) observed in patients treated with only Amb lipid formulations is intriguing. It is noteworthy that 12/15 (80%) of cases exhibited solely gastric involvement, and vascular invasion was documented in only 3 of these cases, suggesting a low degree of invasion as a potential contributing factor to the favourable outcomes observed. Furthermore, half of the survivors received prolonged AFT (2 to 6 months) with liposomal Amb or liposomal Amb followed by PSZ. This experience is limited, but it suggests that when surgery is not possible, prolonged AFT may be an option.

The present review is subject to certain limitations. Firstly, it was retrospective in nature and primarily consists of case reports and case series, thus being limited by the absence of prospective and controlled trials. Even if it has been systematic, some cases may have been overlooked. Secondly, publication bias must be noted, since cases considered unusual are more likely to be reported or published. However, the analysed data relied on stringent inclusion criteria.

**5. Conclusions**

GI and IA mucormycosis are a deadly fungal infection, the diagnosis of which is complicated by its rarity and non-specific clinical presentation. Consequently, these infections are under-suspected. It is therefore vital that suspicion of mucormycosis is raised at the earliest opportunity, and that treatment is commenced promptly, in order to ensure a favourable outcome [26]. In light of this, we propose to suspect GI and IA mucormycosis in patients at risk, as well as those admitted to the ICU with ventilation/nasogastric tube and corticosteroids, exhibiting symptoms such as abdominal distension and pain, and fever,
particularly when associated with GI bleeding. The diagnosis of mucormycosis can be expedited through the utilisation of mycological diagnostic methods, encompassing direct examination and culture on invasive samples (endoscopic biopsy, surgical sample), and Mucorales qPCR performed on tissue and blood samples in select circumstances. These approaches facilitate a swift diagnosis of mucormycosis prior to histological examination. The treatment regimen should encompass AFT, predicated on Amp B derivatives, and surgical intervention when feasible.

**Supplementary Materials:** The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/jof11040298/s1, Figure S1: Distribution (%) of the underling diseased and conditions according to the decade of publication; Figure S2: Distribution (%) of main underlying diseases and conditions according to the country for the five countries with more than 10 reported cases; Table S1: Summary of epidemiological and clinical data reported in the 290 cases of gastrointestinal (GI) and intra-abdominal (IA) mucormycosis that were included in the study; Table S2. Summary of diagnostic, treatment and outcome reported in the 290 cases of gastrointestinal (GI) and intra-abdominal (IA) mucormycosis that were included in the study. Refs [31–276] are cited in the Supplementary Materials.

**Author Contributions:** All the authors contributed to the writing. A.A. original draft preparation and supervision, B.H., A.L.U. and S.J. review and editing. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** All analysed data are included in this paper.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. Vitale, R.G.; de Hoog, G.S.; Schwarz, P.; Dannaoui, E.; Deng, S.; Machouart, M.; Voigt, K.; Wendy, W.; van de Sande, W.W.; Dolatabadi, S.; et al. Antifungal susceptibility and phylogeny of opportunistic members of the order mucorales. *J. Clin. Microbiol.* **2012**, *50*, 66–75. [CrossRef]

2. Walther, G.; Wagner, L.; Kurzai, O. Updates on the Taxonomy of Mucorales with an Emphasis on Clinically Important Taxa. *J. Fungi* **2019**, *5*, 106. [CrossRef] [PubMed]

3. Alqarihi, A.; Kontoyiannis, D.P.; Ibrahim, A.S. Mucormycosis in 2023: An update on pathogenesis and management. *Front. Cell Infect. Microbiol.* **2023**, *13*, 1254919. [CrossRef] [PubMed]

4. Kontoyiannis, D.P.; Wessel, V.C.; Bodey, G.P.; Rolston, K.V. Zygomycosis in the 1990s in a tertiary-care cancer center. *Clin. Infect. Dis.* **2000**, *30*, 851–856. [CrossRef] [PubMed]

5. Marr, K.A.; Carter, R.A.; Crippa, F.; Wald, A.; Corey, L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. *Clin. Infect. Dis.* **2002**, *34*, 909–917. [CrossRef]

6. Ambrosioni, J.; Bouchuiguir-Wafa, K.; Garbino, J. Emerging invasive zygomycosis in a tertiary care center: Epidemiology and associated risk factors. *Int. J. Infect. Dis.* **2010**, *14* (Suppl. S3), e100–e103. [CrossRef]

7. Bitar, D.; Lortholary, O.; Le Strat, Y.; Nicolau, J.; Coignard, B.; Tattevin, P.; Che, D.; Dromer, F. Population-based analysis of invasive fungal infections, France, 2001–2010. *Emerg. Infect. Dis.* **2014**, *20*, 1149–1155. [CrossRef]

8. Dolatabadi, S.; Ahmadi, B.; Rezaei-Matehkolaei, A.; Zarrinfar, H.; Skiada, A.; Mirhendi, H.; Nashibi, R.; Niknejad, F.; Nazeri, M.; Rafiei, A.; et al. Mucormycosis in Iran: A six-year retrospective experience. *J. Mycol. Med.* **2018**, *28*, 269–273. [CrossRef]

9. Prakash, H.; Chakrabarti, A. Epidemiology of Mucormycosis in India. *Microorganisms* **2021**, *9*, 523. [CrossRef]

10. Danion, F.; Letscher-Bru, V.; Guitard, J.; Sitbon, K.; Delliere, S.; Angoulvant, A.; Desoubeaux, G.; Botterel, F.; Bellanger, A.P.; Gargala, G.; et al. Coronavirus Disease 2019-Associated Mucormycosis in France: A Rare but Deadly Complication. *Open Forum Infect Dis.* **2022**, *9*, ofab566. [CrossRef]

11. Spellberg, B.; Edwards, J., Jr.; Ibrahim, A. Novel perspectives on mucormycosis: Pathophysiology, presentation, and management. *Clin. Microbiol. Rev.* **2005**, *18*, 556–569. [PubMed]
12. Tribble, D.R.; Warkentien, T.; Rodriguez, C.; Trauma Infectious Diseases Outcomes Study Group of the Infectious Disease Clinical Research Program. Mucormycosis after a tornado in Joplin, Missouri. *N. Engl. J. Med.* **2013**, *368*, 1067.

13. Warkentien, T.E.; Shaikh, F.; Weintrob, A.C.; Rodriguez, C.J.; Murray, C.K.; Lloyd, B.A.; Ganesan, A.; Aggarwal, D.; Carson, M.L.; Tribble, D.R. Impact of Mucorales and Other Invasive Molds on Clinical Outcomes of Polymicrobial Traumatic Wound Infections. *J. Clin. Microbiol.* **2015**, *53*, 2262–2270.

14. Legrand, M.; Gits-Muselli, M.; Boutin, L.; Garcia-Hermoso, D.; Maurel, V.; Soussi, S.; Benyamina, M.; Ferry, A.; Chaussard, M.; Hamane, S.; et al. Detection of Circulating Mucorales DNA in Critically Ill Burn Patients: Preliminary Report of a Screening Strategy for Early Diagnosis and Treatment. *Clin. Infect. Dis.* **2016**, *63*, 1312–1317.

15. Dang, J.; Goel, P.; Choi, K.J.; Massenzio, E.; Landau, M.J.; Pham, C.H.; Huang, S.; Yenikomshian, H.A.; Spellberg, B.; Gillenwater, T.J. Mucormycosis following burn injuries: A systematic review. *Burns* **2023**, *49*, 15–25.

16. Drogari-Apiranthitou, M.; Skiada, A.; Panayiotides, I.; Vyzantiadis, T.A.; Poulopoulou, A.; Christofidou, M.; Antoniadou, A.; Roilides, E.; Iosifidis, E.; Mamali, V.; et al. Epidemiology of Mucormycosis in Greece; Results from a Nationwide Prospective Survey and Published Case Reports. *J. Fungi* **2023**, *9*, 425. [CrossRef]

17. Roden, M.M.; Zaoutis, T.E.; Buchanan, W.L.; Knudsen, T.A.; Sarkisova, T.A.; Schaufele, R.L.; Sein, M.; Sein, T.; Chiou, C.C.; Chu, J.H. Epidemiology and outcome of zygomycosis: A review of 929 reported cases. *Clin. Infect. Dis.* **2005**, *41*, 634–653.

18. Petrikkos, G.; Skiada, A.; Lortholary, O.; Roilides, E.; Walsh, T.J.; Kontoyiannis, D.P. Epidemiology and clinical manifestations of mucormycosis. *Clin. Infect. Dis.* **2012**, *54* (Suppl S1), S23–S34.

19. Serris, A.; Danion, F.; Lanternier, F. Disease Entities in Mucormycosis. *J. Fungi* **2019**, *5*, 23. [CrossRef]

20. Dioverti, M.V.; Cawcutt, K.A.; Abidi, M.; Sohail, M.R.; Walker, R.C.; Osmon, D.R. Gastrointestinal mucormycosis in immunocompromised hosts. *Mycoses* **2015**, *58*, 714–718.

21. Kaur, H.; Ghosh, A.; Rudramurthy, S.M.; Chakrabarti, A. Gastrointestinal mucormycosis in apparently immunocompetent hosts-A review. *Mycoses* **2018**, *61*, 898–908. [PubMed]

22. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ* **2021**, 372, n71.

23. Donnelly, J.P.; Chen, S.C.; Kauffman, C.A.; Steinbach, W.J.; Baddley, J.W.; Verweij, P.E.; Clancy, C.J.; Wingard, J.R.; Lockhart, S.R.; Groll, A.H.; et al. Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clin. Infect. Dis.* **2020**, *71*, 1367–1376.

24. Rammaert, B.; Lanternier, F.; Zahar, J.R.; Dannaoui, E.; Bougnoux, M.E.; Lecuit, M.; Lortholary, O. Healthcare-associated mucormycosis. *Clin. Infect. Dis.* **2012**, *54* (Suppl S1), S44–S54.

25. Skiada, A.; Lass-Floerl, C.; Klimko, N.; Ibrahim, A.; Roilides, E.; Petrikkos, G. Challenges in the diagnosis and treatment of mucormycosis. *Med. Mycol.* **2018**, *56* (Suppl S1), 93–101.

26. Cornely, O.A.; Alastruey-Izquierdo, A.; Arenz, D.; Chen, S.C.A.; Dannaoui, E.; Hochhegger, B.; Hoenigl, M.; Jensen, H.E.; Lagrou, K.; Lewis, R.E.; et al. Global guideline for the diagnosis and management of mucormycosis: An initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. *Lancet Infect. Dis.* **2019**, *19*, e405–e421.

27. Didehdar, M.; Chegini, Z.; Moradabadi, A.; Anoushirvani, A.A.; Tabaeian, S.P.; Yousefimashouf, M.; Shariati, A. Gastrointestinal mucormycosis: A periodic systematic review of case reports from 2015 to 2021. *Microb. Pathog.* **2022**, *163*, 105388.

28. Song, Y.; Qiao, J.; Giovanni, G.; Liu, G.; Yang, H.; Wu, J.; Chen, J. Mucormycosis in renal transplant recipients: Review of 174 reported cases. *BMC Infect. Dis.* **2017**, *17*, 283.

29. Mustafa, A.; Mahmood, Y.; Hasan, A.; Asaad, H.; Gharib, D.; Hama Hussein, K.; Hasan, K.M.; Ismaeil, D.A.; Hiwa, D.S.; Ali, R.M.; et al. Gastric Mucormycosis: A Systematic Review with Metadata. *Barw. Med. J.* **2024**, *2*, 65–84.

30. Sutherland, J.C.; Jones, T.H. Gastric mucormycosis: Report of case in a Swazi. *S. Afr. Med. J.* **1960**, *34*, 161.

31. Kahn, L.B. Gastric Mucormycosis: Report of a Case with a Review of the Literature. *S. Afr. Med. J.* **1963**, *37*, 1265–1269. [PubMed]

32. Abramowitz, I. Fatal Perforations of the Stomach Due to Mucormycosis of the Gastro-Intestinal Tract. *S. Afr. Med. J.* **1964**, *38*, 93–94. [PubMed]

33. Dannheimer, I.P.; Fouche, W.; Nel, C. Gastric mucormycosis in a diabetic patient. *S. Afr. Med. J.* **1974**, *48*, 838–839. [PubMed]

34. Lawson, H.H.; Schmaman, A. Gastric phycomycosis. *Br. J. Surg.* **1974**, *61*, 743–746.

35. Schulman, A.; Bornman, P.; Kaplan, C.; Morton, P.; Rose, A. Gastrointestinal mucormycosis. *Gastrointest. Radiol.* **1979**, *4*, 385–388.

36. Brullet, E.; Andreu, X.; Elias, J.; Roig, J.; Cervantes, M. Gastric mucormycosis in a patient with acquired immunodeficiency syndrome. *Gastrointest. Endosc.* **1993**, *39*, 106–107.

37. Winkler, S.; Susani, S.; Willinger, B.; Apsner, R.; Rosenkranz, A.R.; Potzi, R.; Berlakovich, G.A.; Pohanka, E. Gastric mucormycosis due to Rhizopus oryzae in a renal transplant recipient. *J. Clin. Microbiol.* **1996**, *34*, 2585–2587.
38. Uchida, T.; Okamoto, M.; Fujikawa, K.; Yoshikawa, D.; Mizokami, A.; Mihara, T.; Kondo, A.; Ohba, K.; Kurohama, K.; Nakashima, M.; et al. Gastric mucormycosis complicated by a gastropleural fistula: A case report and review of the literature. *Medicine* **2019**, *98*, e18142.

39. Corley, D.A.; Lindeman, N.; Ostroff, J.W. Survival with early diagnosis of invasive gastric mucormycosis in a heart transplant patient. *Gastrointest. Endosc.* **1997**, *46*, 452–454.

40. Knoop, C.; Antoine, M.; Vachiery, J.L.; Depre, G.; Alonso-Vega, C.; Struelens, M.; Van Laethem, J.L.; Lingier, P.; Nagy, N.; Jacobs, F.; et al. Gastric perforation due to mucormycosis after heart-lung and heart transplantation. *Transplantation* **1998**, *66*, 932–935.

41. Sharma, M.C.; Gill, S.S.; Kashyap, S.; Kataria, R.; Gupta, D.K.; Sahni, P.; Acharya, S.K. Gastrointestinal mucormycosis--an uncommon isolated mucormycosis. *Indian J. Gastroenterol.* **1998**, *17*, 131–133. [PubMed]

42. Sheu, B.S.; Lee, P.C.; Yang, H.B. A giant gastric ulcer caused by mucormycosis infection in a patient with renal transplantation. *Endoscopy* **1998**, *30*, S60–S61. [PubMed]

43. Barroso, F.; Forcelledo, J.L.; Mayorga, M.; Pena, F.; Marques, F.F.; de la Pena, J. A fatal case of gastric mucormyosis in a heart transplant recipient. *Endoscopy* **1999**, *31*, S2.

44. Cherney, C.L.; Chutuape, A.; Fikrig, M.K. Fatal invasive gastric mucormycosis occurring with emphysematous gastritis: Case report and literature review. *Am. J. Gastroenterol.* **1999**, *94*, 252–256.

45. Al-Rikabi, A.C.; Al-Dohayan, A.D.; Al-Boukai, A.A. Invasive mucormycosis in benign gastric ulcer. *Saudi Med. J.* **2000**, *21*, 287–290.

46. Pickeral, J.J., 3rd; Silverman, J.F.; Sturgis, C.D. Gastric zygomycosis diagnosed by brushing cytology. *Diagn. Cytopathol.* **2000**, *23*, 51–54.

47. Geramizadeh Bita, A.S. Invasive gastric mucormycosis: Report of a case and review of the literature. *Med. J. Islam. Republic Iran* **2001**, *14*, 397–398.

48. Tinmouth, J.; Baker, J.; Gardiner, G. Gastrointestinal mucormycosis in a renal transplant patient. *Can. J. Gastroenterol.* **2001**, *15*, 269–271.

49. Paulo De Oliveira, J.E.; Milech, A. A fatal case of gastric mucormycosis and diabetic ketoacidosis. *Endocr. Pract.* **2002**, *8*, 44–46.

50. Park, Y.S.; Lee, J.D.; Kim, T.H.; Joo, Y.H.; Lee, J.H.; Lee, T.S.; Kim, E.K. Gastric mucormycosis. *Gastrointest. Endosc.* **2002**, *56*, 904–905.

51. Shahapure, A.G.; Patankar, R.V.; Bhatkhande, R. Gastric mucormycosis. *Indian J. Gastroenterol.* **2002**, *21*, 231–232. [PubMed]

52. Vera, A.; Hubscher, S.G.; McMaster, P.; Buckels, J.A. Invasive gastrointestinal zygomycosis in a liver transplant recipient: Case report. *Transplantation* **2002**, *73*, 145–147. [PubMed]

53. Maravi-Poma, E.; Rodriguez-Tudela, J.L.; de Jalon, J.G.; Manrique-Larralde, A.; Torroba, L.; Urtasun, J.; Salvador, B.; Montes, M.; Mellado, E.; Rodríguez-Albarrán, F.; et al. Outbreak of gastric mucormycosis associated with the use of wooden tongue depressors in critically ill patients. *Intensive Care Med.* **2004**, *30*, 724–728. [PubMed]

54. Stamm, B. Mucormycosis of the stomach in a patient with multiple trauma. *Histopathology* **2005**, *47*, 222–223.

55. Prasad, N.; Ram, R.; Satti Reddy, V.; Dakshinamurty, K.V. Non-fatal gastric mucormycosis in a renal transplant patient and review of the literature. *Transpl. Infect. Dis.* **2006**, *8*, 237–241.

56. Devlin, S.M.; Hu, B.; Ippoliti, A. Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. *Dig. Dis. Sci.* **2007**, *52*, 2078–2081.

57. Ho, Y.H.; Wu, B.G.; Chen, Y.Z.; Wang, L.S. Gastric Mucormycosis in an Alcoholic with Review of the Literature. *Tzu Chi Med. J.* **2007**, *19*, 169–172.

58. Vaiphei, K.; Suri, V.; Bhalla, A. Fever, jaundice, altered sensorium, with multiple systemic manifestations. *Indian J. Gastroenterol.* **2007**, *26*, 82–86.

59. Chung, C.S.; Wang, W.L.; Liu, K.L.; Lin, J.T.; Wang, H.P. Green ulcer in the stomach: Unusual mucormycosis infection. *Gastrointest. Endosc.* **2008**, *68*, 566–567.

60. Shiva Prasad, B.N.; Shenoy, A.; Nataraj, K.S. Primary gastrointestinal mucormycosis in an immunocompetent person. *J. Postgrad. Med.* **2008**, *54*, 211–213.

61. Azhar, A.; Calubiran, O.V.; Kilaru, R.M.; Lincoln, J.A.; Moshenyat, I.; Basti, K.; Visconti, E. Patient With Abdominal Pain-Concealing Gastrointestinal Mucormycosis. *Gastroenterol. Hepatol.* **2009**, *5*, 657–661.

62. Nandu, V.; Nagral, A.; Khubchandani, S.; Agrawal, C. A rare cause of upper GI bleeding. *Gut* **2009**, *58*, 1039. [CrossRef] [PubMed]

63. Small, M.; Gill, J.; Reed, J.; Poetter, D.; Goldsmith, S. Isolated gastric mucormycosis—A rare cause of a large gastric ulceration in an immunocompetent host. *Am. J. Gastroenterol.* **2010**, *105*, S172. [CrossRef]

64. Feng, W.; Tseng, C.; Lin, C.; Tseng, K. Nonfatal gastric mucormycosis associated with emphysematous gastritis. *Tzu Chi Med. J.* **2010**, *22*, 146–148. [CrossRef]

65. Johnson, C.B.; Ahmeti, M.; Tyroch, A.H.; Zuckerman, M.J.; Hakim, M.N. Gastric mucormycosis as a cause of life-threatening upper gastrointestinal bleeding in a trauma patient. *Am. Surg.* **2010**, *76*, E76–E77. [CrossRef]
66. Paydar, S.; Baezzat, S.; Fazelzadeh, A.; Geramizadeh, B. A case of gastric zygomycosis in a diabetic patient successfully treated with total gastrectomy. *Middle East. J. Dig. Dis.* **2010**, *2*, 46–48.

67. Pruthvi, B.C.R.C.; Rupashree, S.; Deepak, S.; Vikram, S.; Jayaprakash, B.R.N.; Rao, L. Gastric mucormycosis masquerading as malignancy in an immunocompetent host. *Arab. J. Gastroenterol.* **2010**, *11*, 227–229. [CrossRef]

68. Shenoi, S.; Emery, H.M. Successful treatment of invasive gastric mucormycosis in a child with systemic lupus erythematosus. *Lupus* **2010**, *19*, 646–649. [CrossRef]

69. Woo, P.C.; Lau, S.K.; Ngan, A.H.; Tung, E.T.; Leung, S.Y.; To, K.K.; Cheng, V.C.; Yuen, K.Y. *Lichtheimia hongkongensis* sp. nov., a novel *Lichtheimia* spp. associated with rhinocerebral, gastrointestinal, and cutaneous mucormycosis. *Diagn. Microbiol. Infect. Dis.* **2010**, *66*, 274–284. [CrossRef]

70. Chhaya, V.; Gupta, S.; Arnaout, A. Mucormycosis causing giant gastric ulcers. *Endoscopy* **2011**, *43* (Suppl. S2), E289–E290. [CrossRef]

71. Chang, C.F.; Huang, T.Y.; Lin, T.Y. Unusual giant gastric cardia ulcer. *Intern. Emerg. Med.* **2018**, *13*, 795–796. [CrossRef] [PubMed]

72. Dutta, A.; Roy, M.; Singh, T.; Singh, T. Gastric mucormycosis in an immunocompetent patient. *J. Med. Soc.* **2012**, *26*, 192–194.

73. Naqvi, H.A.; Nadeem Yousaf, M.; Chaudhary, F.S.; Mills, L. Gastric Mucormycosis: An Infection of Fungal Invasion into the Gastric Mucosa in Immunocompromised Patients. *Case Rep. Gastrointest. Med.* **2020**, *2020*, 8876125.

74. Muthuswamy, M. Giant necrotic ulcer: Invasive gastric mucormycosis. *Am. J. Gastroenterol.* **2012**, *107*, S300. [CrossRef]

75. Ryan, O.; Frohlich, S.; Crotty, T.B.; Ryan, D. Rhizopus microsporus infection in an immunocompetent host: A case of immunoparalysis? *Anaesth. Intensive Care.* **2012**, *40*, 367–368.

76. Corey, K.E.; Gupta, N.K.; Agarwal, S.; Xiao, H.D. Case records of the Massachusetts General Hospital. Case 32-2013. A 55-year-old woman with autoimmune hepatitis, cirrhosis, anorexia, and abdominal pain. *N. Engl. J. Med.* **2013**, *369*, 1545–1553. [CrossRef]

77. Irtan, S.; Lamerain, M.; Lesage, F.; Verkarre, V.; Bougnoux, M.E.; Lanternier, F.; Zahar, J.R.; Salvi, N.; Talbotec, C.; Lortholary, O.; et al. Mucormycosis as a rare cause of severe gastrointestinal bleeding after multivisceral transplantation. *Transpl. Infect. Dis.* **2013**, *15*, E235–E238. [CrossRef]

78. Katta, J.G.S.; Narach, T.; Poetter, D.; Kulkarni, P.; Reed, J.; Goldsmith, S.F. Gastric mucormycosis managed with combination antifungal therapy and no surgical debridement. *Infect. Dis. Clin. Pract.* **2013**, *21*, 265–268. [CrossRef]

79. Machicado, J.Y.M.; Wolf, D. Gastric mucormycosis presenting as gastrotintestinal bleeding in a trauma patient. *Am. J. Gastroenterol.* **2013**, *108*, S228–S229. [CrossRef]

80. Bini, R.; Addeo, A.; Maganuco, L.; Fontana, D.; Viora, T.; Leli, R. The role of surgery in a case of diffuse mucormycosis with haematemesis and gastric necrosis. *Ann. R. Coll. Surg. Engl.* **2014**, *96*, e31–e33. [CrossRef]

81. Kaiser, P.; Maggio, E.M.; Pfammatter, T.; Misselwitz, B.; Flury, S.; Schneider, P.M.; Dutkowski, P.; Breitenstein, S.; Müllhaupt, B.; Clavien, P.A.; et al. Histopathological evidence of invasive gastric mucormycosis after transarterial chemoembolization and liver transplantation. *Infection* **2014**, *42*, 779–783. [PubMed]

82. Lee, S.H.; Son, Y.G.; Sohn, S.S.; Ryu, S.W. Successful treatment of invasive gastric mucormycosis in a patient with alcoholic liver cirrhosis: A case report. *Exp. Ther. Med.* **2014**, *8*, 401–404. [PubMed]

83. Kulkarni, R.V.; Thakur, S.S. Invasive Gastric Mucormycosis—A Case Report. *Indian J. Surg.* **2015**, *77* (Suppl. S1), 87–89. [PubMed]

84. Nandwani, A.; Jha, P.K.; Duggal, R.; Kher, V. Invasive gastric mucormycosis and cytomegalovirus infection in an ABO incompatible renal transplant recipient. *Indian J. Nephrol.* **2015**, *25*, 373–376.

85. Nasta, A.M.B.K.; Ranjan, S. An unusual case of gastric gangrene, diaphragmatic gangrene and autosplenectomy due to mucormycosis in a diabetic patient. *Int. J. Case Rep. Images* **2015**, *5*, 95–98.

86. Raviraj, K.S.; Miglani, P.; Garg, A.; Agarwal, P.K. Gastric Mucormycosis with Hemolytic Uremic Syndrome. *J. Assoc. Physicians India* **2015**, *63*, 75–76.

87. Lin, P.Y.; Tang, J.H.; Chang, C.C. A rare cause of GI bleeding in a 56-year-old man. *Gut* **2017**, *66*, 1074.

88. Mittal, T.; Pulle, M.V.; Dey, A.; Malik, V.K. Gastric Mucormycosis Presenting as Gastrocolic Fistula: A Rare Entity. *Indian J. Surg.* **2016**, *78*, 511–512.

89. Ravi, D.; Naqvi, A.; Odashiro, A.; Alowami, S. Gastrointestinal mucormycosis in a patient with COPD and diabetes mellitus. *Can. J. Pathol.* **2016**, *8*, 13.

90. Tathe, S.P.; Dani, A.A.; Chawhan, S.M.; Meshram, S.A.; Randale, A.A.; Raut, W.K. Gastric mucormycosis: Diagnosis by imprint cytology. *Diagn. Cytopathol.* **2016**, *44*, 820–822.

91. Chow, K.L.; McElmeel, D.P.; Brown, H.G.; Tabriz, M.S.; Omi, E.C. Invasive gastric mucormycosis: A case report of a deadly complication in an immunocompromised patient after penetrating trauma. *Int. J. Surg. Case Rep.* **2017**, *40*, 90–93. [PubMed]

92. Chugh, P.; Sasken, H.; Azeez, S.; Kassab, M. Gastric Mucormycosis as a Cause of Upper Gastrointestinal Bleeding in an Immunocompetent Patient. *Am. J. Gastroenterol.* **2017**, *112*, S1059–S1060.

93. Galvan Fernandez, J.; Jimenez Cuenca, M.I.; Molpeceres Martinez, I.; Alvarez-Quinones, M.L. A rare cause of emphysematous infectious gastritis. *Rev. Esp. Enferm. Dig.* **2017**, *109*, 368.
94. Grimaldi, D.; Pradier, O.; Hotchkiss, R.S.; Vincent, J.L. Nivolumab plus interferon-gamma in the treatment of intractable mucormycosis. *Lancet Infect. Dis.* **2017**, *17*, 18.

95. Metussin, D.; Telisinghe, P.U.; Chong, P.L.; Chong, V.H. Gastrointestinal: Gastric mucormycosis. *J. Gastroenterol. Hepatol.* **2017**, *32*, 1537.

96. Nasa, M.; Sharma, Z.; Lipi, L.; Sud, R. Gastric Angioinvasive Mucormycosis in Immunocompetent Adult, A Rare Occurrence. *J. Assoc. Physicians India* **2017**, *65*, 103–104.

97. Sanchez Velazquez, P.; Pera, M.; Gimeno, J.; Zapatero, A.; Nolla, J.; Pera, M. Mucormycosis: An unusual cause of gastric perforation and severe bleeding in immunocompetent patients. *Rev. Esp. Enferm. Dig.* **2017**, *109*, 223–225.

98. Suhaildeen, K.; Majhi, U.; Seshadri, R.A.; Murhekar, K. Gastric Mucormycosis Masquerading as Gastric Malignancy. *Indian J. Surg. Oncol.* **2017**, *8*, 407–410.

99. Abreu, B.; Duarte, M.L.; Santos, L.R.D.; Sementilli, A.; Figueiras, F.N. A rare case of gastric mucormycosis in an immunocompetent patient. *Rev. Soc. Bras. Med. Trop.* **2018**, *51*, 401–402.

100. Alfano, G.; Fontana, F.; Francesca, D.; Assirati, G.; Magistri, P.; Tarantino, G.; Ballarin, R.; Rossi, G.; Franceschini, E.; Codeluppi, M.; et al. Gastric Mucormycosis in a Liver and Kidney Transplant Recipient: Case Report and Concise Review of Literature. *Transplant. Proc.* **2018**, *50*, 905–909.

101. Kim, H.N.; Han, S.A.; Park, H.Y.; Kim, H.W.; Hong, R.; Choi, N.G.; Shin, M.H.; Yoon, N.R.; Kim, H.L.; Chung, J.H.; et al. Successful treatment of invasive gastric mucormycosis in a kidney transplant recipient. *J. Korean Soc. Transplant.* **2018**, *32*, 104–107. [CrossRef]

102. Termos, S.; Othman, F.; Alali, M.; Al Bader, B.M.S.; Alkhadher, T.; Hassanaiah, W.F.; Taqi, A.; Sapkal, A. Total Gastric Necrosis Due to Mucormycosis: A Rare Case of Gastric Perforation. *Am. J. Case Rep.* **2018**, *19*, 527–533. [CrossRef] [PubMed]

103. Adhikari, S.; Gautam, A.R.; Paudyal, B.; Sigdel, K.R.; Basnyat, B. Case Report: Gastric Mucormycosis—A rare but important differential diagnosis of upper gastrointestinal bleeding in an area of Helicobacter pylori endemicity. *Wellcome Open Res.* **2019**, *4*, 5. [CrossRef]

104. Gani, I.; Doroodchi, A.; Falkenstrom, K.; Berry, H.; Lee, W.; Mulloy, L.; Saeed, M.; Kapoor, R. Gastric Mucormycosis in a Renal Transplant Patient Treated with Isavuconazole Monotherapy. *Case Rep. Transplant.* **2019**, *2019*, 9839780. [CrossRef]

105. Guzman Rojas, P.; Robalino Gonzaga, E.; Catania, J.; Moqete, M. An unexpected cause of gastric ulcer. *Am. J. Gastroenterol.* **2019**, *114*, S1506–S1507. [CrossRef]

106. Lankarani, D.; Maka, R.R.; Aziz, H.; Maklad, M.; Jayaraj, M.; Ohning, G. Medical management of gastric mucormycosis in an immunocompetent patient. 2746. *Am. J. Gastroenterol.* **2019**, *114*, S1517–S1518. [CrossRef]

107. Malek, A.; De la Hoz, A.; Arduino, R.; Aisenberg, G.M. Disseminated tuberculosis and gastric mucormycosis coinfection. *IDCases* **2019**, *18*, e00595. [CrossRef]

108. Peng, H.; Xiao, J.; Wan, H.; Shi, J.; Li, J. Severe Gastric Mycormycosis Infection Followed by Cytomegalovirus Pneumonia in a Renal Transplant Recipient: A Case Report and Concise Review of the Literature. *Transplant. Proc.* **2019**, *51*, 556–560. [CrossRef]

109. Sharaan, A.; Alziadat, M.R.; Syed, Z.; Samuel, A.; Yelisetti, R.; Mathew, J.; Ismail, M. Often a deadly fungus; mucor must be among us: A case of angioinvasive gastric mucormycosis with a positive outcome. *Am. J. Respir. Crit. Care Med.* **2019**, *199*, A6582.

110. Monte Junior, E.S.D.; Santos, M.; Ribeiro, I.B.; Luz, G.O.; Baba, E.R.; Hirsch, B.S.; Funari, M.P.; de Moura, E.G.H. Rare and Fatal Gastrointestinal Mucormycosis (Zygomycosis) in a COVID-19 Patient: A Case Report. *Clin. Endosc.* **2020**, *53*, 746–749. [CrossRef]

111. Hameed, T.; Jain, S.K.; Ansari, F.M.; Nizam, A.; Dua, A. Spontaneous Gastric Necrosis: A Rare Presentation of Invasive Mucormycosis in an Immunocompetent Adult. *Case Rep. Infect. Dis.* **2020**, *2020*, 7514051.

112. Jaju, M.; Sagar, R.; Srivastav, S.; Singh, R.; Kumar, V.; Faisal, M. Different types of mucormycosis: Case series. *Int. J. Res. Med. Sci.* **2000**, *8*, 2284–2296.

113. Jung, H.; Kim, G.J.; Oh, T.H. Successful Management of a Rare Gastric Mucormycosis Presenting with Massive Melena in a Polytrauma Patient. *Int. Med. Case Rep. J.* **2020**, *13*, 531–535.

114. Rivas, C.; Gonzalez, M.; Rapoport, G.; Chacon, I. Mucormycosis in an Immunocompromised Patient. *Am. J. Gastroenterol.* **2020**, *115*, S1581.

115. Sharma, D. Successful management of emphysematous gastritis with invasive gastric mucormycosis. *BMJ Case Rep.* **2020**, *13*, e231297.

116. Ghuman, S.S.; Sindhu, P.; Buxi, T.B.S.; Sheth, S.; Yadav, A.; Rawat, K.S.; Sud, S. CT appearance of gastrointestinal tract mucormycosis. *Abdom. Radiol.* **2021**, *46*, 1837–1845.

117. Huang, H.; Xie, L.; Zheng, Z.; Yu, H.; Tu, L.; Cui, C.; Yu, J. Mucormycosis-induced upper gastrointestinal ulcer perforation in immunocompetent patients: A report of two cases. *BMC Gastroenterol.* **2021**, *21*, 311.

118. Rai, A.; Gajula, B.; Kumar, N.; Malik, A. Gastric Perforation Secondary to Fungal Gastritis in an Immuno-Competent Adult. *Cureus* **2021**, *13*, e13156.

119. Yuvaraj, M.; Mathapati, P.M.; Seena, C.R.; Ramaswami, S. Gastric mucormycosis with splenic invasion a rare abdominal complication of COVID-19 pneumonia. *J. Clin. Imaging Sci.* **2021**, *11*, 62.
120. Bhaskar, B.K.; Gutte, S.H.; Gurjar, M.; Saran, S.; Rahul, R.; Sengar, P. A Rare Case Report of Intra-abdominal Mucormycosis Complicating Acute Pancreatitis. *Indian J. Crit. Care Med.* **2022**, *26*, 736–738.

121. Chauhan, N.K.; Agarwal, A.; Dutt, N.; Yadav, T.; Kochar, R. Pulmonary embolism and gastric bleed with disseminated mucormycosis—Treading dangerous waters. *Monaldi Arch. Chest Dis.* **2022**, *93*, 2418. [CrossRef] [PubMed]

122. Ozbek, L.; Topcu, U.; Manay, M.; Esen, B.H.; Bektas, S.N.; Aydin, S.; Özdemir, B.; Khostelidi, S.N.; Klimko, N.; Cornely, O.; et al. COVID-19-associated mucormycosis: A systematic review and meta-analysis of 958 cases. *Clin. Microbiol. Infect.* **2023**, *29*, 722–731. [CrossRef] [PubMed]

123. Khsiba, A.; Moalla, M.; Nechi, S.; Bani, A.; Elloumi, A.; Jemal, S.; Azouz, M.M.; Medhioub, M.; Hamzaoui, L. Fatal invasive gastric mucormycosis: Two case reports. *Clin. Case Rep.* **2022**, *10*, e6330. [CrossRef] [PubMed]

124. Sachan, A.; Choudhury, A.; Sasani, A.; Mandavdhare, H. Two tales of gastric mucormycosis S3683. *Am. J. Gastroenterol.* **2022**, *117*, S2310. [CrossRef]

125. Safwan, M.; Khan, S.; Belthazar, A.; Sasidharan, M. Primary invasive gastric mucormycosis presenting as Meleney's gangrene: A case report and review of literature. *Libyan J. Med. Sci.* **2021**, *5*, 171–173. [CrossRef]

126. Albtoosh, A.S.; Shaf'ei, M.; Al Hayek, S.; Ramdan, L.I.; Abu Shahin, N.; Alzyoud, M.; Farah, R. A successfully treated gastric mucormycosis in an immunocompetent patient: Case report and literature review. *Clin. Case Rep.* **2023**, *11*, e7540. [CrossRef]

127. Arora, S.; Singh, A.; Prasad, P.; Rahul Singh, R. Case Reports on Black Fungus of the Gastrointestinal Tract: A New Complication in COVID-19 Patients. *Korean J. Gastroenterol.* **2023**, *81*, 221–225. [CrossRef]

128. Bhowmik, S.; Jadav, D.; Aggarwal, D.; Shekhawat, R.S. Gastric mucormycosis. *Autops. Case Rep.* **2023**, *13*, e2023421. [CrossRef]

129. Khanna, D.; Sahu, P. Primary gastric mucormycosis after COVID. *Gastrointest. Endosc.* **2023**, *97*, 1159–1160. [CrossRef]

130. Kim, J.; Wee, D.; Behin, D.; Brandt, L. Gastric mucormycosis in an immunosuppressed patient following dual pancreas-kidney ransplant. *Am. J. Gastroenterol.* **2023**, *118*, S2624. [CrossRef]

131. Malakar, S.; Elhence, A.; Prasad, P.; Ghoshal, U.C.; Pandey, G.; Mohindra, S. Primary gastric mucormycosis presenting with post-Coronavirus disease-19 upper gastrointestinal bleed. *Indian J. Gastroenterol.* **2023**, *42*, 736–737. [CrossRef] [PubMed]

132. Marco, D.N.; Gonzalez-Munoz, B.; Doti, P.I. Gastric mucormycosis presenting as fever of unknown origin in an immunocompetent host after heatstroke. *Pol. Arch. Intern. Med.* **2023**, *133*, 16513. [CrossRef] [PubMed]

133. Chaudhari, V.; Amarapurkar, A.D.; Rane, P. Mucormycosis Masquerading as Gastric Tumor. *ACG Case Rep. J.* **2024**, *11*, e01401. [CrossRef] [PubMed]

134. de Lucena, L.A.; de Oliveira, F.G.; de Andrade, M.M.P.; de Paula, K.C.; Praxedes, M.R.G.; de Oliveira, R.A. Mucormycosis-induced hypercalcemia: A case report. *CEN Case Rep.* **2024**, *13*, 66–71. [CrossRef]

135. He, D.; Wang, Z. Multiple Gastric Ulcers in An Immunosuppressed Patient with COVID-19 Infection caused by Mucormycosis. *J. Gastrointestin. Liver Dis.* **2024**, *33*, 16. [CrossRef]

136. Huang, W.; Li, L.; Gao, J.; Kang, L. Gastric mucormycosis presenting as diffuse thickening of the gastric wall with enhancement. *Rev. Esp. Enferm. Dig.* **2024**, *116*, 167–168. [CrossRef]

137. Ji, R. Mucormycosis mimicking portal hypertensive haemorrhage as a complication of alcoholic liver cirrhosis: A case report. *BMC Infect. Dis.* **2024**, *24*, 136.

138. Lalwani, S.; Govindasamy, M.; Gupta, M.; Siraj, F.; Varma, V.; Mehta, N.; Kumaran, V.; Mohan, N.; Chopra, P.; Arora, A.; et al. Gastrointestinal mucormycosis—Four cases with different risk factors, involving different anatomical sites. *Indian J. Gastroenterol.* **2012**, *31*, 139–143. [CrossRef]

139. Perez Fernandez, A.; Rubio Mateos, J.M.; Sanchez Fernandez, M.J. Gastric ulcer due to mucormycosis in a critical patient. *Rev. Esp. Enferm. Dig.* **2020**, *112*, 576–577. [CrossRef]

140. Raju, B.; Santhanakumar, K.S.; Kesavachandran, U. Gastrointestinal involvement of unusual Mucormycete Syncephalastrum racemosum in a diabetic patient with adenocarcinoma: Rare case presentation with review of literature. *Infection* **2020**, *48*, 791–797. [CrossRef]

141. Taams, M.; Bade, P.G.; Thomson, S.R. Post-traumatic abdominal mucormycosis. *Injury* **1992**, *23*, 390–392. [PubMed]

142. Saltmarsh, G.; Plurad, D.; Bricker, S.; Bongard, F.; Neville, A.; Putnam, B.; Kim, D. Gastric necrosis and recurrent small bowel perforation resulting from gastrointestinal mucormycosis. *Am. Surg.* **2014**, *80*, E293–E294. [PubMed]

143. Ju, J.H.; Park, H.S.; Shin, M.J.; Yang, C.W.; Kim, Y.S.; Choi, Y.J.; Song, H.J.; Kim, S.W.; Chung, I.S.; Bang, B.K. Successful treatment of massive lower gastrointestinal bleeding caused by mixed infection of cytomegalovirus and mucormycosis in a renal transplant recipient. *Am. J. Nephrol.* **2001**, *21*, 232–236. [PubMed]

144. Kaneko, Y.; Oinuma, K.I.; Terachi, T.; Arimura, Y.; Niki, M.; Yamada, K.; Kakeya, H.; Mizutani, T. Successful Treatment of Intestinal Mycosis Caused by a Simultaneous Infection with *Lichtheimia ramosa* and *Aspergillus calidoustus*. *Intern. Med.* **2018**, *57*, 2421–2424.

145. Nidhi, M.; Sadia, K.; Khatri, A.; Arnab, G.; Khan, N.A. Gastrointestinal Mucormycosis in a two-year-old child: A clinical and radiological enigma. *Med. Mycol. Case Rep.* **2019**, *26*, 5–9.
146. Hyvernat, H.; Dunais, B.; Burel-Vandenbos, F.; Guidicelli, S.; Bernardin, G.; Gari-Toussaint, M. Fatal peritonitis caused by Rhizopus microsporus. *Med. Mycol.* **2010**, *48*, 1096–1098.

147. Wotiye, A.B.; Ks, P.; Ayele, B.A. Invasive intestinal mucormycosis in a 40-year old immunocompetent patient—A rarely reported clinical phenomenon: A case report. *BMC Gastroenterol.* **2020**, *20*, 61.

148. Liu, Q.; Chen, P.; Xin, L.; Zhang, J.; Jiang, M. A rare intestinal mucormycosis caused by *Lichtheimia ramosa* in a patient with diabetes: A case report. *Front. Med.* **2024**, *11*, 1435239.

149. Mungazi, S.G.; Zambuko, B.; Muchuweti, D.; Muguti, E.G.; Mlotshwa, S. Fatal haemorrhagic duodenal mucormycosis in a non-immunocompromised host: A case report. *Med. Mycol. Case Rep.* **2017**, *17*, 1–3.

150. Sun, M.; Hou, X.; Wang, X.; Chen, G.; Zhao, Y. Gastrointestinal Mucormycosis of the Jejunum in an Immunocompetent Patient: A Case Report. *Medicine* **2017**, *96*, e6360.

151. Poyuran, R.; Dharan, B.S.; Sandhyamani, S.; Narasimhaiah, D. Mucormycosis-induced ileocecal perforation: A case report and review of literature. *J. Postgrad. Med.* **2020**, *66*, 48–50. [CrossRef] [PubMed]

152. Bhat, V.; Anitha, S.; Thomas, A.; Kanavi, J.V.; Thomas, A. Intestinal Perforation Secondary to Mucormycosis Associated with Puerperal Sepsis. *Cureus* **2021**, *13*, e17428. [CrossRef] [PubMed]

153. Gupta, S.; Jayashree, M.; Chakrabarti, A.; Sodhi, K.S.; Kanojia, R.P.; Mitra, S. Invasive Gastrointestinal Mucormycosis: A Master Masquerader. *Pediatr. Infect. Dis. J.* **2018**, *37*, 1067–1070. [CrossRef]

154. Aruni, A., Sr.; Tandup, C.; Chowdhury, A., Sr.; Roy, A.; Jha, B. Illicit Drug Use a Risk Factor for Ileal Mucormycosis Presenting with Acute Abdomen. *Cureus* **2020**, *12*, e12213. [CrossRef]

155. Himaal Dev, G.J.; Venkategowda, P.M.; Sutar, A.R.; Shankar, V. Intestinal mucormycosis in an adult with H1N1 pneumonia on extracorporeal membrane oxygenation. *Ann. Card. Anaesth.* **2021**, *24*, 92–94.

156. Manda, D.; Sen, I.; Thakral, P.; Das, S.S.; Cb, V.; Malik, D. Invasive Fungal Infection in COVID-19-Recovered Patient Detected on 18F-FDG-Labeled Leukocytes PET/CT Scan. *Clin. Nucl. Med.* **2022**, *47*, e177–e179. [CrossRef]

157. Zulpi, P.K.; Kulkarni, V.K.; Rani, H.; Halgeri, A.; Agnihotri, A. Double Whammy Due to Coronavirus Disease-2019: Invasive Small Bowel Mucormycosis with Recent-Onset Diabetic Ketoacidosis Presenting as Diffuse Fecal Peritonitis in a 12-Year-Old Girl. *J. Indian Assoc. Pediatr. Surg.* **2023**, *28*, 59–61. [CrossRef]

158. Chethan, K.; Prasad, S.; Ramachandra, L. Ileocolic mucormycosis—An unusual cause of a mass in the right iliac fossa. *Can. J. Infect. Dis. Microbiol.* **2012**, *23*, e65–e66. [CrossRef]

159. Yadav, S.; Sharma, A.; Kothari, N.; Bhatia, P.K.; Goyal, S.; Goyal, A. Mucormycosis: A Case Series of Patients Admitted in Non-COVID-19 Intensive Care Unit of a Tertiary Care Center during the Second Wave. *Indian J. Crit. Care Med.* **2021**, *25*, 1193–1196.

160. Sarkardeh, M.; Meftah, E.; Mohammadzadeh, N.; Koushki, J.; Sadrzadeh, Z. COVID-19 and Intestinal Ischemia: A Multicenter Case Series. *Front. Med.* **2022**, *9*, 879996. [CrossRef]

161. Martinello, M.; Nelson, A.; Bignold, L.; Shaw, D. "We are what we eat"! Invasive intestinal mucormycosis: A case report and review of the literature. *Med. Mycol. Case Rep.* **2012**, *1*, 52–55. [PubMed]

162. Kumar, C.; Jain, P.; Wadhwa, N.; Diwaker, P.; Nirupma Panikar, K. Nosocomial Jejunal Mucormycosis—An Unusual Cause of Perforation Peritonitis. *Iran. J. Pathol.* **2017**, *12*, 295–300. [PubMed]

163. Budhiraja, R.; Bhargava, S.; Sood, N. Jejunal stricture due to mucormycosis. *Trop. Doct.* **2019**, *49*, 318–320.

164. Bhana, M.; Laher, N.; McGrath, N.G.; Moeng, M.S. Small bowel mucormycosis: An unexpected case in a penetrating trauma survivor. *Int. J. Surg. Case Rep.* **2023**, *113*, 109071.

165. Watson, M.; Fong, R.; Schoemaker, D.; Due, S. Black fungus: Gastrointestinal invasive mucormycosis causing small bowel perforation, gastric and peristomal ulceration. *ANZ J. Surg.* **2024**, *94*, 252–253.

166. Paliwal, P.; Rahar, S.; Sharma, A.; Gupta, D.; Ahuja, A.; Chauhan, D.S. Intestinal mucormycosis in a patient with COVID-19: A case report. *Indian J. Pathol. Microbiol.* **2022**, *65*, 475–477.

167. Sriperumbuduri, S.; Kalidindi, K.; Megha, H.; Guditi, S.; Taduri, G. An unusual case of gastrointestinal mucormycosis in a patient with nephrotic syndrome. *Indian J. Nephrol.* **2017**, *27*, 145–147.

168. Singh, R.P.; Gupta, N.; Kaur, T.; Gupta, A. Rare case of gastrointestinal mucormycosis with colonic perforation in an immunocompetent patient with COVID-19. *BMJ Case Rep.* **2021**, *14*, e244096.

169. Nagy-Agren, S.E.; Chu, P.; Smith, G.J.; Waskin, H.A.; Altice, F.L. Zygomycosis (mucormycosis) and HIV infection: Report of three cases and review. *J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.* **1995**, *10*, 441–449.

170. Cebisli, E.; Ulgen-Tekerek, N.; Dursun, O.; Koker, A.; Kisaoglu, A.; Artan, R.; Soyucen, E.; Elpek, G.O. Intestinal Mucormycosis in a Child with Maple Syrup Urine Disease After Orthotopic Liver Transplant. *Exp. Clin. Transplant.* **2023**, *21*, 375–379.

171. Saraf, P.; Naresh Bharti, J. Mucormycosis presenting as intestinal perforation: A pathologist perspective. *Arab. J. Gastroenterol.* **2024**, *25*, 234–236. [PubMed]

172. Eiser, A.R.; Slifkin, R.F.; Neff, M.S. Intestinal mucormycosis in hemodialysis patients following deferoxamine. *Am. J. Kidney Dis.* **1987**, *10*, 71–73. [PubMed]
173. Yinadsawaphan, T.; Ngamskulrungroj, P.; Chalermwai, W.; Dhitinanmuang, W.; Angkasekwinai, N. Gastrointestinal mucormycosis due to Rhizopus microsporus following Streptococcus pyogenes toxic shock syndrome in an HIV patient: A case report. *BMC Infect. Dis.* **2020**, *20*, 817.

174. Li, C.; Zhu, H.; Tan, Y.; Liu, D. Gastrointestinal bleeding due to duodenal mucormycosis in an immunocompetent host mimicking malignancy. *Rev. Esp. Enferm. Dig.* **2019**, *111*, 961-962.

175. Evert, K.; Dienemann, T.; Brochhausen, C.; Lunz, D.; Lubnow, M.; Ritzka, M.; Keil, F.; Trummer, M.; Scheiter, A.; Salzberger, B.; et al. Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation. *Virchows Arch.* **2021**, *479*, 97-108.

176. Marco del Pont, J.; De Cicco, L.; Gallo, G.; Llera, J.; De Santibanez, E.; D'Agostino, D. Hepatic arterial thrombosis due to Mucor species in a child following orthotopic liver transplantation. *Transpl. Infect. Dis.* **2000**, *2*, 33-35.

177. Mekeel, K.L.; Hemming, A.W.; Reed, A.I.; Matsumoto, T.; Fujita, S.; Schain, D.C.; Nelson, D.R.; Dixon, L.R.; Fujikawa, T. Hepatic mucormycosis in a renal transplant recipient. *Transplantation* **2005**, *79*, 1636.

178. Zhan, H.X.; Lv, Y.; Zhang, Y.; Liu, C.; Wang, B.; Jiang, Y.Y.; Liu, X.M. Hepatic and renal artery rupture due to Aspergillus and Mucor mixed infection after combined liver and kidney transplantation: A case report. *Transplant. Proc.* **2008**, *40*, 1771-1773.

179. Abboud, C.S.; Bergamasco, M.D.; Baia, C.E.; Lallee, M.P.; Zan, A.S.; Zamorano, M.M.; Pereira, O.I.; Mies, S. Case report of hepatic mucormycosis after liver transplantation: Successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy. *Transplant. Proc.* **2012**, *44*, 2501-2502.

180. Chaudhary, R.J.; Choudhary, N.S.; Saraf, N.; Gautam, D.; Piplani, T.; Thiagrajan, S.; Bhangui, P.; Saigal, S.; Rastogi, A.; Soin, A.S. Delayed Graft Dysfunction due to Invasive Hepatic Mucormycosis After Living Donor Liver Transplantation. *J. Clin. Exp. Hepatol.* **2020**, *10*, 629-632.

181. Teira, R.; Trinidad, J.M.; Eizaguirre, B.; Ortiz, J.; Santamaria, J.M. Zygomycosis of the spleen in a patient with the acquired immunodeficiency syndrome. *Mycoses* **1993**, *36*, 437-439. [CrossRef] [PubMed]

182. Luo, S.; Huang, X.; Li, Y.; Wang, J. Isolated splenic mucormycosis secondary to diabetic ketoacidosis: A case report. *BMC Infect. Dis.* **2022**, *22*, 596. [CrossRef] [PubMed]

183. Chakrabarti, A.; Ghosh, A.; Prasad, G.S.; David, J.K.; Gupta, S.; Das, A.; Sakhuja, V.; Panda, N.K.; Singh, S.K.; Das, S.; et al. *Apophysomyces elegans*: An emerging zygomycete in India. *J. Clin. Microbiol.* **2003**, *41*, 783-788. [CrossRef] [PubMed]

184. Gupta, V.; Singh, S.K.; Kakkar, N.; Jain, S.; Kalra, N.; Sakia, U.N. Splenic and renal mucormycosis in a healthy host: Successful management by aggressive treatment. *Trop. Gastroenterol.* **2010**, *31*, 57-58.

185. O'Connor, C.; Farrell, C.; Fabre, A.; Eaton, D.; Redmond, K.; McSharry, D.G.; Conneely, J.B.; Shields, C.J.; Egan, J.J.; Hannan, M.M. Near-fatal mucormycosis post-double lung transplant presenting as uncontrolled upper gastrointestinal haemorrhage. *Med. Mycol. Case Rep.* **2018**, *21*, 30-33. [CrossRef]

186. Jain, M.; Tyagi, R.; Tyagi, R.; Jain, G. Post-COVID-19 Gastrointestinal Invasive Mucormycosis. *Indian J. Surg.* **2022**, *84*, 545-547. [CrossRef]

187. Okhuysen, P.C.; Rex, J.H.; Kapusta, M.; Fife, C. Successful treatment of extensive posttraumatic soft-tissue and renal infections due to Apophysomyces elegans. *Clin. Infect. Dis.* **1994**, *19*, 329-331. [CrossRef]

188. Durila, M.; Pavlicek, P.; Hadacova, I.; Nahlovsky, J.; Janeckova, D. Endogenous Heparinoids May Cause Bleeding in Mucor Infection and can be Detected by Nonactivated Thromboelastometry and Treated by Recombinant Activated Factor VII: A Case Report. *Medicine* **2016**, *95*, e2933. [CrossRef]

189. Sedlacek, M.; Cotter, J.G.; Suriawinata, A.A.; Kaneko, T.M.; Zuckerman, R.A.; Parsonnet, J.; Block, C.A. Mucormycosis peritonitis: More than 2 years of disease-free follow-up after posaconazole salvage therapy after failure of liposomal amphotericin, B. *Am. J. Kidney Dis.* **2008**, *51*, 302-306. [CrossRef]

190. Polo, J.R.; Luno, J.; Menarguez, C.; Gallego, E.; Robles, R.; Hernandez, P. Peritoneal mucormycosis in a patient receiving continuous ambulatory peritoneal dialysis. *Am. J. Kidney Dis.* **1989**, *13*, 237-239. [CrossRef]

191. Fergie, J.E.; Fitzwater, D.S.; Einstein, P.; Leggiadro, R.J. Mucor peritonitis associated with acute peritoneal dialysis. *Pediatr. Infect. Dis. J.* **1992**, *11*, 498-500. [PubMed]

192. Adam, R.D.; Hunter, G.; DiTomasso, J.; Comerci, G., Jr. Mucormycosis: Emerging prominence of cutaneous infections. *Clin. Infect. Dis.* **1994**, *19*, 67-76. [PubMed]

193. Khan, Z.U.; Chugh, T.D. Invasive fungal infections in Kuwait: A retrospective study. *Indian J. Chest Dis. Allied Sci.* **2000**, *42*, 279-287. [PubMed]

194. Monecke, S.; Hochauf, K.; Gottschlich, B.; Ehricht, R. A case of peritonitis caused by *Rhizopus microsporus*. *Mycoses* **2006**, *49*, 139-142.

195. Pimentel, J.D.; Dreyer, G.; Lum, G.D. Peritonitis due to Cunninghamella bertholletiae in a patient undergoing continuous ambulatory peritoneal dialysis. *J. Med. Microbiol.* **2006**, *55 Pt 1*, 115-118.

196. Nayak, S.; Satish, R.; Gokulnath Savio, J.; Rajalakshmi, T. Peritoneal mucormycosis in a patient on CAPD. *Perit. Dial. Int.* **2007**, *27*, 216-217.
197. Bhutada, K.; Borkar, S.S.; Mendiratta, D.K.; Shende, V.R. Successful treatment of peritonitis by *C. bertholletiae* in a chronic kidney failure patient on continuous ambulatory peritoneal dialysis after kidney rejection. *Singap. Med. J.* **2012**, *53*, e106–e109.

198. Pamidimukkala, U.; Sudhaharan, S.; Kancharla, A.; Vemu, L.; Challa, S.; Karanam, S.D.; Chavali, P.; Prakash, H.; Ghosh, A.K.; Gupta, S.; et al. Mucormycosis due to Apophysomyces species complex- 25 years' experience at a tertiary care hospital in southern India. *Med. Mycol.* **2020**, *58*, 425–433.

199. Dalgic, B.; Bukulmez, A.; Sari, S. Pyogenic liver abscess and peritonitis due to *Rhizopus oryzae* in a child with Papillon-Lefevre syndrome. *Eur. J. Pediatr.* **2011**, *170*, 803–805.

200. Verma, G.R.; Lobo, D.R.; Walker, R.; Bose, S.M.; Gupta, K.L. Disseminated mucormycosis in healthy adults. *J. Postgrad. Med.* **1995**, *41*, 40–42.

201. Kaushik, R. Primary cutaneous zygomycosis in India. *Indian J. Surg.* **2012**, *74*, 468–475. [CrossRef] [PubMed]

202. Chakrabarti, A.; Kumar, P.; Padhye, A.A.; Chatha, L.; Singh, S.K.; Das, A.; Wig, J.D.; Kataria, R.N. Primary cutaneous zygomycosis due to Saksenaea vasiformis and *Apophysomyces elegans*. *Clin. Infect. Dis.* **1997**, *24*, 580–583. [CrossRef] [PubMed]

203. Mathews, M.S.; Raman, A.; Nair, A. Nosocomial zygomycotic post-surgical necrotizing fasciitis in a healthy adult caused by *Apophysomyces elegans* in south India. *J. Med. Vet. Mycol.* **1997**, *35*, 61–63. [CrossRef]

204. Kumar, A.; Khilnani, G.C.; Aggarwal, S.; Kumar, S.; Banerjee, U.; Xess, I. Primary cutaneous mucormycosis in an immunocompetent host: Report of a case. *Surg. Today* **2003**, *33*, 319–322. [CrossRef]

205. Thami, G.P.; Kaur, S.; Bawa, A.S.; Chander, J.; Mohan, H.; Bedi, M.S. Post-surgical zygomycotic necrotizing subcutaneous infection caused by *Absidia corymbifera*. *Clin. Exp. Dermatol.* **2003**, *28*, 251–253. [CrossRef]

206. Kerbaul, F.; Guidon, C.; Collart, F.; Lepidi, H.; Cayatte, B.; Bonnet, M.; Bellezza, M.; Métras, D.; Gouin, F. Abdominal wall mucormycosis after heart transplantation. *J. Cardiothorac. Vasc. Anesth.* **2004**, *18*, 822–823. [CrossRef]

207. Padmaja, I.J.; Ramani, T.V.; Kalyani, S. Cutaneous zygomycosis: Necrotising fascitis due to Saksenaea vasiformis. *Indian J. Med. Microbiol.* **2006**, *24*, 58–60. [CrossRef]

208. Belfiori, R.; Terenzi, A.; Marchesini, L.; Repetto, A. Absidia Corymbifera in an immune competent accident victim with multiple abdominal injuries: Case report. *BMC Infect. Dis.* **2007**, *7*, 46. [CrossRef]

209. Tilak, R.; Raina, P.; Gupta, S.K.; Tilak, V.; Prakash, P.; Gulati, A.K. Cutaneous zygomycosis: A possible postoperative complication in immunocompetent individuals. *Indian J. Dermatol. Venereol. Leprol.* **2009**, *75*, 596–599. [CrossRef]

210. Tapish, S.; Taha, M.; Naresh, G.; Neeraj, D.; Malik Vinod, K. Primary mucormycosis of abdominal wall: A rare fungal infection in an immunocompetent patient. *Indian J. Surg.* **2010**, *72* (Suppl S1), 306–308. [CrossRef]

211. Alharbi, M.; Jhinger, R.K.; Wuerz, T.; Walkty, A. Marked peripheral eosinophilia due to prolonged administration of posaconazole. *JMM Case Rep.* **2017**, *4*, e005100.

212. Ram, R.; Swarnalatha, G.; Prasad, N.; Dakshinamurty, K.V. Exit site infection due to Zygomycosis resulting in abdominal wall necrosis in a continuous ambulatory peritoneal dialysis patient. *Nephrol. Dial. Transplant.* **2007**, *22*, 266–267.

213. Patel, A.K.; Vora, H.J.; Patel, K.K.; Patel, B. Elderly diabetic patient with surgical site mucormycosis extending to bowel. *J. Glob. Infect. Dis.* **2010**, *2*, 186–188.

214. Zhao, L.; Wang, C.X.; Zhang, L.; Tu, X.A.; Wang, W.; Chen, Y.; Liu, L.S. Mucormycosis extending from the surgical wound to the transplanted kidney: Case report and literature review. *Exp. Clin. Transplant.* **2012**, *10*, 403–405.

215. Paonam, S.; Bag, S.; Mavuduru, R.S.; Agarwal, M.M.; Mandal, A.K. Isolated bilateral renal mucormycosis masquerading as renal abscess in an immunocompetent individual: A lesson learnt. *Case Rep. Urol.* **2014**, *2014*, 304380.

216. Narayanaswamy, S.; Goradia, R.; Bellurkar, A.; Patwardhan, S. Isolated renal mucormycosis masquerading as emphysematous pyelonephritis. *BMJ Case Rep.* **2023**, *16*, e254501.

217. Stein, A.; Schmaman, A. Rupture of the stomach due to mucormycosis. *S Afr. J. Surg.* **1965**, *3*, 123–129.

218. Deal, W.B.; Johnson, J.E., 3rd. Gastric phycomycosis. Report of a case and review of the literature. *Gastroenterology* **1969**, *57*, 579–586.

219. Branton, M.H.; Johnson, S.C.; Brooke, J.D.; Hasbargen, J.A. Peritonitis due to Rhizopus in a patient undergoing continuous ambulatory peritoneal dialysis. *Rev. Infect. Dis.* **1991**, *13*, 19–21.

220. Norden, G.; Bjorck, S.; Persson, H.; Svalander, C.; Li, X.G.; Edebo, L. Cure of zygomycosis caused by a lipase-producing Rhizopus rhizopodiformis strain in a renal transplant patient. *Scand. J. Infect. Dis.* **1991**, *23*, 377–382.

221. Vadeboncoeur, C.; Walton, J.M.; Raisen, J.; Soucy, P.; Lau, H.; Rubin, S. Gastrointestinal mucormycosis causing an acute abdomen in the immunocompromised pediatric patient—Three cases. *J. Pediatr. Surg.* **1994**, *29*, 1248–1249. [PubMed]

222. Hosseini, M.; Lee, J. Gastrointestinal mucormycosis mimicking ischemic colitis in a patient with systemic lupus erythematosus. *Am. J. Gastroenterol.* **1998**, *93*, 1360–1362. [PubMed]

223. Guardia, J.A.; Bourgoignie, J.; Diego, J. Renal mucormycosis in the HIV patient. *Am. J. Kidney Dis.* **2000**, *35*, E24.

224. Herbrecht, R.; Letscher-Bru, V.; Bowden, R.A.; Kusne, S.; Anaissie, E.J.; Graybill, J.R.; Noskin, G.A.; Oppenheim, B.A.; Andrès, E.; Pietrelli, L.A. Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion. *Eur. J. Clin. Microbiol. Infect. Dis.* **2001**, *20*, 460–466.
225. Nannini, E.C.; Paphitou, N.I.; Ostrosky-Zeichner, L. Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: Report of 2 cases and review of the literature. *Diagn. Microbiol. Infect. Dis.* **2003**, *46*, 49–54.

226. Serna, J.H.; Wanger, A.; Dosekun, A.K. Successful treatment of mucormycosis peritonitis with liposomal amphotericin B in a patient on long-term peritoneal dialysis. *Am. J. Kidney Dis.* **2003**, *42*, E14–E17.

227. Alkhunaizi, A.M.; Amir, A.A.; Al-Tawfiq, J.A. Invasive fungal infections in living unrelated renal transplantation. *Transplant. Proc.* **2005**, *37*, 3034–3037.

228. Sethi, J.; Ramachandran, R.; Kohli, H.S.; Gupta, K.L. Isolated renal mucormycosis in a patient with Idiopathic CD4 lymphocytopenia. *BMJ Case Rep.* **2018**, 2018, bcr201825234.

229. Deja, M.; Wolf, S.; Weber-Carstens, S.; Lehmann, T.N.; Adler, A.; Ruhnke, M.; Tintelnot, K. Gastrointestinal zygomycosis caused by *Mucor indicus* in a patient with acute traumatic brain injury. *Med. Mycol.* **2006**, *44*, 683–687.

230. Taj-Aldeen, S.J.; Almaslamani, M.; Theelen, B.; Boekhout, T. Phylogenetic analysis reveals two genotypes of the emerging fungus *Mucor indicus*, an opportunistic human pathogen in immunocompromised patients. *Emerg. Microbes Infect.* **2017**, *6*, e63.

231. Manchikalapati, P.; Canon, C.L.; Jhala, N.; Eloubeidi, M.A. Gastrointestinal zygomycosis complicating heart and lung transplantation in a patient with Eisenmenger's syndrome. *Dig. Dis. Sci.* **2005**, *50*, 1181–1183. [CrossRef] [PubMed]

232. Jung, J.H.; Choi, H.J.; Yoo, J.; Kang, S.J.; Lee, K.Y. Emphysematous gastritis associated with invasive gastric mucormycosis: A case report. *J. Korean Med. Sci.* **2007**, *22*, 923–927. [CrossRef] [PubMed]

233. Berne, J.D.; Villarreal, D.H.; McGovern, T.M.; Rowe, S.A.; Moore, F.O.; Norwood, S.H. A fatal case of posttraumatic gastric mucormycosis. *J. Trauma* **2009**, *66*, 933–935. [CrossRef] [PubMed]

234. Islam, J.; Thomson, S.R.; Tudor, G.; Khan, Z.; Mjoli, M. Ileosigmoid knot complicated by gastric and splenic mucormycosis: A lethal combination. *BMJ Case Rep.* **2009**, 2009, bcr10.2008.1049. [CrossRef]

235. Mezhir, J.J.; Mullane, K.M.; Zarling, J.; Satoskar, R.; Pai, R.K.; Roggin, K.K. Successful nonoperative management of gastrointestinal mucormycosis: Novel therapy for invasive disease. *Surg. Infect.* **2009**, *10*, 447–451. [CrossRef]

236. Van Sickels, N.; Hoffman, J.; Stuke, L.; Kempe, K. Survival of a patient with trauma-induced mucormycosis using an aggressive surgical and medical approach. *J. Trauma.* **2011**, *70*, 507–509. [CrossRef]

237. Rudler, M.; Barret, M.; Poynard, T.; Thabut, D. Gastric mucormycosis: A rare cause of gastrointestinal bleeding in cirrhosis. *Clin. Res. Hepatol. Gastroenterol.* **2012**, *36*, e32–e33. [CrossRef]

238. Tan, J.; Manickam, R.; Pisharam, J.; Telisinghe, P.; Chong, V.H. Mucormycosis—A possible trigger pathogen for encapsulating peritoneal sclerosis. *Perit. Dial. Int.* **2012**, *32*, 479–481. [CrossRef]

239. Enani, M.A.; Alharthi, B.N.; Dewanjee, N.; Bhat, N.A.; Fagih, M. Spontaneous gastric ulcer perforation and acute spleen infarction caused by invasive gastric and splenic mucormycosis. *J. Glob. Infect. Dis.* **2014**, *6*, 122–124. [CrossRef]

240. Gaut, D.; Cone, B.D.; Gregson, A.L.; Agopian, V.G. Gastrointestinal Mucormycosis After Orthotopic Liver Transplantation Presenting as Femoral Nerve Palsy: A Case Report and Review of the Literature. *Transplant. Proc.* **2017**, *49*, 1608–1614. [CrossRef]

241. Izaguirre-Anariba, D.E.; Chee, F.; Thet, Z.; Lanza, J. An Interesting Case of a 57-Year-Old Male with an Upper Gastrointestinal Bleeding and Obstructive Uropathy with Bilateral Hydronephrosis Diagnosed with Systemic Mucormycosis. *Case Rep. Infect. Dis.* **2018**, 2018, 6283701.

242. Aggarwal, P.; Patel, H.; Gonzalez, L.; Brown, L.; Agarwal, A.; Speeg, K. Invasive Colonic Mucormycosis in an Immunocompromised Postliver Transplant Patient. *ACG Case Rep. J.* **2020**, *7*, e00450.

243. Reis, F.P.D.; Campos, S.V.; Aiello, V.D.; Duarte, M.I.S.; Samano, M.N.; Pego-Fernandes, P.M. Gastrointestinal mucormycosis post lung transplantation. *Braz. J. Infect. Dis.* **2019**, *23*, 368–370. [PubMed]

244. Rotundo, L. A fatal case of disseminated gastric mucormycosis with emphysematous gastritis. *Am. J. Gastroenterol.* **2019**, *114*, S1505–S1506.

245. Sehmbey, G.; Malik, R.; Kosa, D.; Srinivasan, I.; Chuang, K.Y.; Bellapravalu, S. Gastric Ulcer and Perforation due to Mucormycosis in an Immunocompetent Patient. *ACG Case Rep. J.* **2019**, *6*, e00154.

246. Shankaralingappa, S. Unsuspected invasive gastrointestinal mucormycosis masquerading as inflammatory bowel disease: A pathologist's perspective. *Indian J. Pathol. Microbiol.* **2019**, *62*, 332–334.

247. Petrochko, J.M.; Abrahamian, G.; Cigarroa, F.; Thomas, E. Colonic mucormycosis in solid organ transplantation: Case report and review of the literature (colonic mucormycosis after DDLT). *Transpl. Infect. Dis.* **2020**, *22*, e13362.

248. Shah, C.; Zimmerman, S.; McKinney, J.; Ebers, A. Colonic mucormycosis in an immunocompetent patient with endocarditis. *IDCases* **2020**, *20*, e00773.

249. Chiang, T.H.; Lee, Y.W.; Tan, J.H.; Kao, C.C.; Chang, C.C.; Fang, K.C. Mucormycosis causing massive lower gastrointestinal bleeding: A case report. *BMC Gastroenterol.* **2021**, *21*, 272.

250. Hammami, F.; Koubaa, M.; Chakroun, A.; Smaoui, F.; Marrakchi, C.; Hentati, N.; Mzali, R.; Rekik, K.; Jemaa, M.B. Survival of an immuno-competent patient from splenic and gastric mucormycosis-case report and review of the literature. *J. Mycol. Med.* **2021**, *31*, 101174.
251. Martin-Blais, R.; Pathak, S.; Fitzwater, S.; Dawson, D.W.; Sisk, A.E.; Farmer, D.G.; Venick, R.; Yeganeh, N. Intestinal mucormycosis initially identified by next-generation sequencing of cell-free, D.N.A. *Transpl. Infect. Dis.* **2021**, *23*, e13656.

252. Varshney, V.K.; Swami, A.; Thirunavukkarasu, B.; Agarwal, A.; Baid, G. Synchronous Small Bowel Gangrene with Pyelonephritis Secondary to Mucormycosis: A Disastrous Complication of COVID-19 Pandemic. *Cureus* **2021**, *13*, e15911.

253. Kyuno, D.; Kubo, T.; Tsujiwaki, M.; Sugita, S.; Hosaka, M.; Ito, H.; Harada, K.; Takasawa, A.; Kubota, Y.; Takasawa, K.; et al. COVID-19-associated disseminated mucormycosis: An autopsy case report. *World J. Clin. Cases.* **2022**, *10*, 10358–10365. [PubMed]

254. Ito, H.; Kakizaki, R.; Harada, K.; Kyuno, D.; Kubo, T.; Bunya, N.; Kasai, T.; Uemura, S.; Narimatsu, E. Disseminated mucormycosis in a patient with severe COVID-19 on venovenous extracorporeal membrane oxygenation: A case report. *IDCases* **2022**, *29*, e01578.

255. Meshram, H.S.; Kumar, D.; Kute, V.B. Rare and Unusual Follow-up Sequelae of Coronavirus Disease 2019: Splenic Mucormycosis in a Renal Transplant Recipient. *Transplant Proc.* **2022**, *54*, 1554–1556.

256. Ralaizanaka, B.M.; Razafindrazoto, C.I.; Bolot, E.; Bors, G.; Housson-Wetzel, S.; Razafimahefa, S.H.; Ramanampamonjy, R.M.; Claude, P. Gastrointestinal Mucormycosis-Induced Massive Lower Gastrointestinal Bleeding, Rectal Perforation, and Pulmonary Embolism: A Long Diagnostic Pathway in a Case Report. *Clin. Exp. Gastroenterol.* **2022**, *15*, 145–151.

257. Banerjee, N.; Lodha, M.; Kompally, P.; Chawla, S. Post-COVID-19 Intestinal and Mesenteric Mucormycosis. *Am. Surg.* **2023**, *89*, 2770–2773.

258. Rathi, C.; Shinde, R.K.; Dighe, S.P.; Lamture, Y.; Mahawar, R. Gastric Necrosis: A Rare Complication of Gastric Mucormycosis. *Cureus* **2023**, *15*, e35810.

259. Li, K.W.; Wen, T.F.; Li, G.D. Hepatic mucormycosis mimicking hilar cholangiocarcinoma: A case report and literature review. *World J. Gastroenterol.* **2010**, *16*, 1039–1042.

260. Rabin, E.R.; Lundberg, G.D.; Mitchell, E.T. Mucormycosis in severely burned patients. Report of two cases with extensive destruction of the face and nasal cavity. *N. Engl. J. Med.* **1961**, *264*, 1286–1289.

261. Virmani, R.; Connor, D.H.; McAllister, H.A. Cardiac mucormycosis. A report of five patients and review of 14 previously reported cases. *Am. J. Clin. Pathol.* **1982**, *78*, 42–47. [PubMed]

262. Straatsma, B.R.; Zimmerman, L.E.; Gass, J.D. Phycomycosis. A clinicopathologic study of fifty-one cases. *Lab. Investig.* **1962**, *11*, 963–985. [PubMed]

263. Agger, W.A.; Maki, D.G. Mucormycosis. A complication of critical care. *Arch. Intern. Med.* **1978**, *138*, 925–927.

264. Gupta, K.L.; Joshi, K.; Pereira, B.J.; Singh, K. Disseminated mucormycosis presenting with acute renal failure. *Postgrad. Med. J.* **1987**, *63*, 297–299.

265. Nakamura, M.; Weil, W.B., Jr.; Kaufman, D.B. Fatal fungal peritonitis in an adolescent on continuous ambulatory peritoneal dialysis: Association with deferoxamine. *Pediatr. Nephrol.* **1989**, *3*, 80–82.

266. Singh, N.; Gayowski, T.; Singh, J.; Yu, V.L. Invasive gastrointestinal zygomycosis in a liver transplant recipient: Case report and review of zygomycosis in solid-organ transplant recipients. *Clin. Infect. Dis.* **1995**, *20*, 617–620.

267. Stoebner, P.E.; Gaspard, C.; Mourad, G.; Beraud, J.J.; Meynadier, J.; Meunier, L. Fulminant mucormycosis in a renal transplant recipient. *Acta Derm. Venereol.* **2000**, *80*, 305.

268. Tsaousis, G.; Koutsouri, A.; Gatsiou, C.; Paniara, O.; Peppas, C.; Chalevelakis, G. Liver and brain mucormycosis in a diabetic patient type II successfully treated with liposomal amphotericin B. *Scand. J. Infect. Dis.* **2000**, *32*, 335–337.

269. Sehgal, A.; Raghavendran, M.; Kumar, D.; Srivastava, A.; Dubey, D.; Kumar, A. Rhinocerebral mucormycosis causing basilar artery aneurysm with concomitant fungal colonic perforation in renal allograft recipient: A case report. *Transplantation* **2004**, *78*, 949–950.

270. Gimeno-García, A.; Parra-Blanco, A.; Nicolás-Pérez, D.; Manzano-Sanz, C.; Méndez-Medina, R.; Quintero, E. Mucormycosis with gastric involvement in a patient with severe atheromatous vascular disease. *Dig. Endosc.* **2006**, *18*, 144–146.

271. Alexander, B.D.; Schell, W.A.; Siston, A.M.; Rao, C.Y.; Bower, W.A.; Balajee, S.A.; Howell, D.N.; Moore, Z.S.; Noble-Wang, J.; Rhyne, J.A.; et al. Fatal Apophysomyces elegans infection transmitted by deceased donor renal allografts. *Am. J. Transplant.* **2010**, *10*, 2161–2167. [PubMed]

272. Arena, V.; De-Giorgio, F.; Pennacchia, I.; Manna, R.; Vetrugno, G.; Stigliano, E.; Milic, N.; Gasbarrini, G.; Abenavoli, L. Haemophagocytic syndrome associated with mucormycosis infection. *Int. J. Immunopathol. Pharmacol.* **2012**, *25*, 751–755. [PubMed]

273. Gurevich, M.; Levi, I.; Steinberg, R.; Shonfeld, T.; Shapiro, R.; Israeli, M.; Sprecher, H.; Shalit, I.; Mor, E. Mucormycosis in a liver allograft: Salvage re-transplantation and targeted immunosuppressive management. *Transpl. Infect. Dis.* **2012**, *14*, E97–E101.

274. Nam, Y.; Jung, J.; Park, S.S.; Kim, S.J.; Shin, S.J.; Choi, J.H.; Kim, M.; Yoon, H.E. Disseminated mucormycosis with myocardial involvement in a renal transplant recipient. *Transpl. Infect. Dis.* **2015**, *17*, 890–896.
275. Alqhamdi, S.; Idress, B.; Alharbi, A.; Aljurais, N. Case report: Disseminated pulmonary mucormycosis involving spleen in diabetic patient with aggressive surgical approach. *Int. J. Surg. Case Rep.* **2019**, *54*, 42–46.

276. Sami, C.A.; Rashed, H.M.; Khan, A.H.; Barai, L.; Arafat, S.M. Disseminated mucormycosis: An unusual case of ascites with bone marrow invasion. *IDCases* **2022**, *29*, e01553.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.